TIDMAZN
RNS Number : 8083V
AstraZeneca PLC
02 February 2017
AstraZeneca PLC
2 February 2017 07:00
Full-Year and Q4 2016 Results
Performance in line with expectations; 2017 has the potential to
be a defining year
Financial Summary
FY 2016 Q4 2016
------------------------- ----------------------
$m % change $m % change
------- ------
CER(1) Actual CER Actual
----------------------------------- ------- ------- ------- ------ ----- -------
Total Revenue 23,002 (5) (7) 5,585 (12) (13)
Product Sales 21,319 (8) (10) 5,260 (15) (15)
Externalisation Revenue 1,683 59 58 325 77 69
Reported Operating Profit 4,902 9 19 2,533 n/m n/m
Core Operating Profit(2) 6,721 (7) (3) 2,026 15 30
Reported Earnings Per Share (EPS) $2.77 9 24 $1.46 93 n/m
Core EPS $4.31 (5) 1 $1.21 9 29
----------------------------------- ------- ------- ------- ------ ----- -------
-- The fall in Product Sales primarily reflected the entry of
Crestor generic medicines in the US; Crestor represents the last
anticipated blockbuster(3) patent expiry, ahead of significant
late-stage pipeline news flow
-- Good progress on cost control in the year, reflecting the evolving shape of the business:
- Reported and Core R&D cost growth of 2% to $5,890m and 5%
to $5,631m, respectively, including the absorption of the R&D
costs of Acerta Pharma and ZS Pharma
- Reported and Core SG&A costs declined by 12% to $9,413m and by 9% to $8,169m, respectively
-- Reported EPS increased by 9% in the year to $2.77, reflecting
a revaluation of acquisition-related liabilities. A 5% fall in Core
EPS was driven by a corresponding rate of decline in Total
Revenue
-- A second interim dividend of $1.90 per share has been
declared, bringing the dividend for the full year to $2.80 per
share. The Board reaffirms its commitment to the Company's
progressive dividend policy
Commercial Highlights
The Growth Platforms grew by 5% in the year (Q4 2016: Up by 3%).
Highlights included:
-- Emerging Markets: 6% growth (Q4 2016: Up by 7%) to $5,794m,
supported by China, up by 10% to $2,636m
-- Diabetes: Growth of 11%, as Farxiga became the Company's largest-selling Diabetes medicine
-- Japan: A sales decline of 3% to $2,184m, reflecting the
biennial price reduction in the year
-- Brilinta: Sales grew by 39% to $839m; on track to be a blockbuster medicine
-- Respiratory: A decline of 3% to $4,753m (Q4 2016: Down by
5%), reflecting US pricing pressure for Symbicort
-- New Oncology: Strong sales of $664m (Q4 2016: $216m);
Tagrisso delivered sales of $423m in its first year
Achieving Scientific Leadership
The pipeline-driven progress of AstraZeneca continued in the
year. Twelve potential new medicines are in
Phase III/under regulatory review, primarily within the three
therapy areas of Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Oncology pipeline, which attracted over 40% of
R&D investment in the year, is progressing ahead of the
Company's expectations, in particular Tagrisso and the
Immuno-Oncology programmes. The table below highlights successes in
the late-stage pipeline since the last results announcement:
Regulatory Submission - durvalumab - bladder cancer
Acceptances (US)
- Tagrisso - lung cancer (AURA3
trial) (US, EU)
- Faslodex - breast cancer (1st
line) (US, EU)
- roxadustat - anaemia (CN) (rolling
submission)
- benralizumab - severe, uncontrolled
asthma (US, EU)
----------------------- ---------------------------------------
Other Key Developments - Priority Review Designation:
durvalumab (US)
- Priority Review Designation:
Tagrisso (US)
----------------------- ---------------------------------------
Pascal Soriot, Chief Executive Officer, commenting on the
results said:
"Our financial results in the year were in line with
expectations and reflected the ongoing transition of our company.
We brought a sharper strategic focus to our three main therapy
areas, boosting pipeline productivity further as we saw with
Priority Review Designations for durvalumab and Tagrisso, as well
as regulatory submission acceptances for durvalumab in bladder
cancer and for benralizumab in severe, uncontrolled asthma. Our
underlying business is growing as a new AstraZeneca emerges, driven
by competitive franchises and Emerging Markets.
2017 has the potential to be a turning point for our company as
we near the end of our patent-expiry period and bring new medicines
to patients across the globe. We anticipate defining data, in
particular from our outstanding pipeline of Immuno-Oncology and
targeted treatments. This year we have the opportunity to launch
several life-changing medicines for cancer, respiratory and
metabolic diseases. It is an exciting time as we rapidly approach
the inflection point for our anticipated return to long-term
growth, built on the solid foundations of a science-led
pipeline."
FY 2017 Guidance
The Company provides guidance on Total Revenue and Core EPS
only. All measures in this section are at constant exchange
rates(1) :
Total Revenue A low to mid single-digit percentage decline
-------------- ---------------------------------------------
Core EPS A low to mid teens percentage decline*
-------------- ---------------------------------------------
*The Core EPS guidance anticipates a normalised effective Core
tax rate of 16-20% (FY 2016: 11%).
Guidance is subject to base-case assumptions of the progression
of the pipeline and the extensive level of news flow listed on the
following page. Variations in performance between quarters can be
expected to continue, with year-on-year comparisons expected to
ease in the second half of FY 2017, when the impact of the entry of
Crestor generic medicines in the US will annualise.
The Company presents Core EPS guidance. It is unable to provide
guidance on a Reported/GAAP basis because the Company cannot
reliably forecast material elements of the Reported/GAAP result,
including the fair-value adjustments arising on acquisition-related
liabilities, intangible-asset impairment charges and
legal-settlement provisions. Please refer to the section
'Cautionary Statements Regarding Forward-Looking Statements' at the
end of this announcement.
In addition to the guidance listed above, the Company also
provides indications in other areas of the Income Statement. The
sum of Externalisation Revenue and Other Operating Income in FY
2017 is anticipated to be ahead of that in FY 2016. Sustainable and
ongoing income(4) is expected to increase further as a proportion
of Externalisation Revenue in FY 2017. Core R&D costs are
expected to be broadly in line with those in FY 2016 and the
Company anticipates a further reduction in Core SG&A costs,
reflecting the evolving shape of the business. A full explanation
of these items is listed in the Operating & Financial
Review.
FY 2017 Currency Impact
Based only on average exchange rates in January 2017 and the
Company's published currency sensitivities, there is expected to be
a low single-digit percentage adverse impact from currency
movements on Total Revenue and Core EPS in the year. Further
details on currency sensitivities are contained within the
Operating and Financial Review.
Notes
1. All growth rates and guidance are shown at constant exchange
rates (CER) unless specified otherwise.
2. See the Operating and Financial Review for a definition of
Core financial measures and a reconciliation of Core to Reported
financial measures.
3. The term 'blockbuster' is defined as a medicine with Product
Sales in excess of $1bn over a period of 12 months.
4. Sustainable and ongoing income is defined as Externalisation
Revenue excluding upfront receipts.
Pipeline: Forthcoming Major News Flow
Innovation is critical to addressing unmet patient needs and is
at the heart of the Company's growth strategy. The focus on
research and development is designed to yield strong results from
the pipeline.
H1 2017 Faslodex - breast cancer (1st line): Regulatory
decision (JP)
Lynparza - ovarian cancer (2nd line): Regulatory
submission
Lynparza - breast cancer: Data readout
Tagrisso - lung cancer (AURA3): Regulatory
decision (US)
durvalumab - bladder cancer: Regulatory decision
(US)
durva +/- treme - lung cancer (ARCTIC): Data
readout
acalabrutinib - blood cancer: Data readout,
regulatory submission (US) (Phase II)(#)
Bydureon - autoinjector: Regulatory submission
(US)
saxagliptin/dapagliflozin - type-2 diabetes:
Regulatory decision (US)
ZS-9 (sodium zirconium cyclosilicate) - hyperkalaemia:
Regulatory decision (US, EU)
Bevespi - COPD: Regulatory submission (EU)
benralizumab - severe, uncontrolled asthma:
Regulatory submission (JP)
--------- -----------------------------------------------------------
Mid-2017 durva +/- treme - lung cancer (MYSTIC): Data
readout
--------- -----------------------------------------------------------
H2 2017 Faslodex - breast cancer (1st line): Regulatory
decision (US, EU)
Lynparza - breast cancer: Regulatory submission
Lynparza - ovarian cancer (1st line): Data
readout
Tagrisso - lung cancer: Regulatory decision
(CN)
Tagrisso - lung cancer (AURA3): Regulatory
decision (EU)
Tagrisso - lung cancer (1st line): Data readout
durvalumab - lung cancer (PACIFIC): Data readout,
regulatory submission (US)
durva +/- treme - lung cancer (MYSTIC): Regulatory
submission
durva +/- treme - lung cancer (ARCTIC): Regulatory
submission
durva +/- treme - head & neck cancer (KESTREL):
Data readout
moxetumomab - leukaemia: Data readout
benralizumab - severe, uncontrolled asthma:
Regulatory decision (US)
tralokinumab - severe, uncontrolled asthma:
Data readout
--------- -----------------------------------------------------------
2018 Lynparza - ovarian cancer (1st line): Regulatory
submission
Tagrisso - lung cancer (1st line): Regulatory
submission
durva + treme - lung cancer (NEPTUNE): Data
readout
durva +/- treme - head & neck cancer (KESTREL):
Regulatory submission
durva +/- treme - head & neck cancer (EAGLE):
Data readout, regulatory submission
durva +/- treme - bladder cancer (DANUBE):
Data readout, regulatory submission
moxetumomab - leukaemia: Regulatory submission
selumetinib - thyroid cancer: Data readout,
regulatory submission
Brilinta - type-2 diabetes / coronary artery
disease: Data readout, regulatory submission
Bydureon - cardiovascular (CV) outcomes trial:
Data readout, regulatory submission
roxadustat - anaemia: Data readout (AstraZeneca-sponsored
trials), regulatory submission
Duaklir - COPD: Regulatory submission (US)
benralizumab - severe, uncontrolled asthma:
Regulatory decision (EU)
tralokinumab - severe, uncontrolled asthma:
Regulatory submission
PT010 - COPD: Data readout, regulatory submission
anifrolumab - lupus: Data readout
--------- -----------------------------------------------------------
The term 'data readout' in this section refers to Phase III data
readouts, unless specified otherwise.
(#) Potential fast-to-market opportunity ahead of randomised,
controlled trials.
Results Presentation
A presentation and accompanying live webcast for investors and
analysts, hosted by management, will begin at 12.30pm UK time
today. Details can be accessed via astrazeneca.com/investors.
Reporting Calendar
The Company intends to publish its first quarter financial
results on 27 April 2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Esra Erkal-Paler UK/Global +44 203 749 5638
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Operating And Financial Review
_______________________________________________________________________________________
All narrative on growth and results in this section is based on
CER unless stated otherwise. Financial figures are in US$ millions
($m). The performance shown in this announcement covers the twelve
and three-month periods to 31 December 2016 (the year and the
quarter, respectively) compared to the twelve and three-month
periods to 31 December 2015.
Core measures, which are presented in addition to Reported
financial information, are non-GAAP measures provided to enhance
understanding of the Company's underlying financial performance.
Core financial measures are adjusted to exclude certain significant
items, such as:
- amortisation and impairment of intangible assets, including
impairment reversals but excluding any charges relating to IT
assets
- charges and provisions related to global restructuring
programmes (this will include such charges that relate to the
impact of global restructuring programmes on capitalised IT
assets)
- other specified items, principally comprising legal
settlements and acquisition-related costs, which include fair-value
adjustments and the imputed finance charge relating to contingent
consideration on business combinations
Details on the nature of these measures are provided on page 64
of the Annual Report and Form 20-F Information 2015.
Total Revenue
FY 2016 Q4 2016
------------------------- ---------------------- ---------------------
$m % CER change $m % CER change
------------------------- ------- ------------- ------ -------------
Product Sales 21,319 (8) 5,260 (15)
Externalisation Revenue 1,683 59 325 77
Total Revenue 23,002 (5) 5,585 (12)
------------------------- ------- ------------- ------ -------------
Based on actual exchange rates, Total Revenue declined by 7% in
the year and by 13% in the quarter.
Product Sales
The level of decline in Product Sales was driven by the impact
of the entry of Crestor generic medicines in the US, as well as the
reducing impact of Nexium generic medicines in the US. Sales of
Crestor and Nexium in the US declined by 57% and 39%, respectively.
Overall US Product Sales declined by 22% in the year to $7,365m (Q4
2016: Down by 37% to $1,618m). Product Sales in Europe declined by
3% in the year to $5,064m (Q4 2016: Down by 3% to $1,332m).
Within Product Sales, the Growth Platforms grew by 5% in the
year, representing 63% of Total Revenue:
Growth Platform FY 2016 Q4 2016
------------------ ---------------------------------- ----------------------------------
Product Sales ($m) % CER change Product Sales ($m) % CER change
------------------ ------------------- ------------- ------------------- -------------
Emerging Markets 5,794 6 1,486 7
Respiratory 4,753 (3) 1,210 (5)
Diabetes 2,427 11 598 3
Japan 2,184 (3) 591 (5)
Brilinta 839 39 236 37
New Oncology(1) 664 n/m 216 n/m
Total(2) 14,491 5 3,728 3
------------------ ------------------- ------------- ------------------- -------------
(1) New Oncology comprises Lynparza, Iressa (US) and
Tagrisso.
(2) Total Product Sales for Growth Platforms adjusted to remove
duplication on a medicine and regional basis.
Externalisation Revenue
Where AstraZeneca retains a significant economic interest in
medicines or potential new medicines, income from transactions is
reported as Externalisation Revenue in the Company's financial
statements. The table below illustrates the level of sustainable
and ongoing income(1) within the total of Externalisation Revenue.
Sustainable and ongoing income is anticipated to grow as a
proportion of Externalisation Revenue over time.
FY 2016 Q4 2016
---------------------------------- ---------------------------------
$m % of Total % change $m % of Total % change
------ ----------- ------------- ---- ----------- --------------
CER Actual CER Actual
----------------------------------------------- ------ ----------- ---- ------- ---- ----------- ----- -------
Royalties(2) 119 7 69 58 45 14 222 230
Milestones 237 14 35 33 10 3 (87) (87)
----------------------------------------------- ------ ----------- ---- ------- ---- ----------- ----- -------
Sub-total Sustainable and Ongoing
Externalisation Revenue 356 21 45 40 55 17 (37) (40)
----------------------------------------------- ------ ----------- ---- ------- ---- ----------- ----- -------
Upfront Receipts 1,327 79 63 63 270 83 172 171
----------------------------------------------- ------ ----------- ---- ------- ---- ----------- ----- -------
Total Externalisation Revenue 1,683 100 59 58 325 100 77 69
----------------------------------------------- ------ ----------- ---- ------- ---- ----------- ----- -------
(1) Sustainable and ongoing income is defined as Externalisation
Revenue excluding upfront receipts.
(2) Royalties in FY 2016 included those derived from the Aspen
Global Incorporated (Aspen) transaction highlighted below.
Externalisation Revenue recognised in the year amounted to
$1,683m. Highlights included:
Medicine Partner Region $m
---------------------- ---------------------------------- --------------- ------
Global (excl.
Anaesthetics Aspen - initial revenue US) 520
China Medical System
Holdings Ltd -commercialisation
Plendil rights - initial revenue China 298
Aralez Pharmaceuticals
Trading DAC (Aralez)
Toprol-XL - initial revenue US 175
Tralokinumab LEO Pharma A/S (LEO Pharma)
- atopic dermatitis - initial revenue Global 115
Eli Lilly and Company
AZD3293 (Lilly) - milestone revenue Global 100
Nexium OTC Pfizer Inc. (Pfizer)
20mg - milestone revenue Global 93
ProStrakan Group plc
- commercialisation rights
- initial and milestone
Moventig revenue EU 78
Others 304
Total 1,683
--------------------------------------------------------------------------- ------
Examples of sustainable and ongoing Externalisation Revenue
streams are shown below:
Announcement Medicine Partner Region Externalisation Revenue
Date
------------- ------------- ---------------- --------- -----------------------------------------------------------
4 October Toprol-XL Aralez US
2016 * Initial $175m milestone
* Up to $48m milestone and sales-related revenue
* Mid-teen percentage royalties on sales
1 July 2016 Tralokinumab LEO Pharma Global
- atopic * Initial $115m milestone
dermatitis
* Up to $1bn in commercially-related milestones
* Up to mid-teen tiered percentage royalties on sales
9 June 2016 Anaesthetics Aspen Global
(excl. * Initial $520m milestone
US)
* Up to $250m in sales-related revenue
* Double-digit percentage trademark royalties on sales
1 September Brodalumab - Valeant Global,
2015 psoriasis Pharmaceuticals later * Initial $100m milestone
International, amended
Inc. (Valeant) to US
* Pre-launch milestone up to $170m
* Sales-related royalties up to $175m
19 March Movantik Daiichi Sankyo US
2015 * Initial $200m milestone
* Up to $625m in Product Sales-related revenue
------------- ------------- ---------------- --------- -----------------------------------------------------------
Product Sales
_______________________________________________________________________________________
The performance of key medicines is shown below, with a
geographical split shown in Notes 8 and 9.
FY 2016 Q4 2016
------------------------------------ ----------------------
$m % of Total % change $m % change
------- ----------- ------
CER Actual CER Actual
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Oncology
Iressa 513 2 (5) (6) 118 (11) (9)
Tagrisso 423 2 n/m n/m 147 n/m n/m
Lynparza 218 1 n/m n/m 62 72 72
Legacy:
Faslodex 830 4 19 18 222 19 20
Zoladex 816 4 - - 235 13 19
Casodex 247 1 (9) (7) 60 (8) (5)
Arimidex 232 1 (6) (7) 57 (7) (5)
Others 104 - (26) (21) 29 - 12
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Total Oncology 3,383 16 20 20 930 26 30
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Cardiovascular & Metabolic Diseases
Brilinta 839 4 39 36 236 37 36
Farxiga 835 4 72 70 239 57 57
Onglyza 720 3 (6) (8) 149 (21) (22)
Bydureon 578 3 - - 142 (8) (8)
Byetta 254 1 (19) (20) 55 (22) (24)
Legacy:
Crestor 3,401 16 (32) (32) 631 (53) (52)
Seloken/Toprol-XL 737 3 9 4 178 14 11
Atacand 315 1 (8) (13) 81 (5) (6)
Others 437 2 (26) (28) 100 (31) (32)
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Total Cardiovascular & Metabolic Diseases 8,116 38 (13) (14) 1,811 (26) (26)
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Respiratory
Symbicort 2,989 14 (10) (12) 740 (13) (14)
Pulmicort 1,061 5 8 5 288 8 5
Tudorza/Eklira 170 1 (9) (11) 36 (23) (23)
Daliresp/Daxas 154 1 48 48 41 28 28
Duaklir 63 - n/m n/m 19 58 58
Others 316 1 27 22 86 37 32
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Total Respiratory 4,753 22 (3) (5) 1,210 (5) (6)
Other
Nexium 2,032 10 (18) (19) 491 (15) (13)
Seroquel XR 735 3 (27) (28) 118 (51) (51)
Synagis 677 3 2 2 302 10 10
Losec/Prilosec 276 1 (17) (19) 59 (23) (23)
FluMist/Fluenz 104 - (59) (64) 67 (60) (65)
Movantik/Moventig 91 - n/m n/m 26 73 73
Others 1,152 5 (20) (23) 246 (34) (35)
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Total Other 5,067 24 (19) (20) 1,309 (25) (25)
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Total Product Sales 21,319 100 (8) (10) 5,260 (15) (15)
------------------------------------------- ------- ----------- ----- ------- ------ ----- -------
Product Sales Summary
_______________________________________________________________________________________
ONCOLOGY
Full-year sales of $3,383m; up by 20%.
Oncology sales represented 16% of Total Product Sales.
Iressa (full-year sales of $513m; down by 5%)
Sales in the US amounted to $23m, with sales in Europe declining
by 5% to $120m. The Company prioritised the launch of Tagrisso in
the year, given its potential impact for patients and the Company.
Emerging Markets sales (defined in the Regional Product Sales
section on page 13) declined by 10% to $233m. China sales declined
by 16% to $116m, a result of a new price following national
reimbursement listing obtained in June 2016. Strong competition
from branded and generic medicines in Korea also contributed to the
decline.
Tagrisso (full-year sales of $423m)
In the second half of the year, sales of Tagrisso surpassed
those of Iressa, with Tagrisso becoming the leading AstraZeneca
medicine for the treatment of lung cancer. Regulatory approvals
were granted in a number of markets, including Brazil, Hong Kong,
Singapore, Taiwan and the United Arab Emirates; the Company
anticipates additional regulatory approvals and reimbursement
decisions in due course. To date, Tagrisso has received regulatory
approval in 46 countries worldwide.
Sales in the US amounted to $254m. After regulatory approval in
the EU and Japan earlier in the year, sales in the year were $76m
in Europe and $82m in Japan.
On 27 December 2016, a third-party, blood-based
companion-diagnostic test for Tagrisso was approved in Japan. The
test is designed to confirm the presence of a T790M mutation in
patients. Similarly, the blood-based companion-diagnostic partner
test for Tagrisso was approved in the US on 29 September 2016.
Lynparza (full-year sales of $218m)
Lynparza was available to patients in 31 countries by the end of
2016, with regulatory reviews underway in seven additional
countries including Russia, Brazil and Singapore. Almost 5,000
patients globally have been prescribed Lynparza since the first
launch in December 2014. Sales in the US increased by 81% in the
year to $127m; Lynparza now has a high market penetration. Sales in
Europe increased to $81m, following a number of successful
launches.
Legacy: Faslodex (full-year sales of $830m; up by 19%)
Sales in the US in the year increased by 23% to $438m, mainly
driven by an expanded label in March 2016 for 2nd-line advanced or
metastatic breast cancer, in combination with palbociclib. Europe
full-year sales increased by 11% to $228m. An increase in demand in
Japan led to sales growth of 12% to $63m. China sales, up by 91% to
$20m, supported Emerging Markets sales of $96m, representing an
increase of 25%.
Legacy: Zoladex (full-year sales of $816m; stable)
The stable performance was attributed to Europe sales (down by
4% to $156m) and Established Rest Of World (ROW) sales (down by 7%
to $270m) being offset by favourable sales performances in the US
(up by 25% to $35m) and Emerging Markets (up by 6% to $355m).
CARDIOVASCULAR & METABOLIC DISEASES
Full-year sales of $8,116m; down by 13%.
Cardiovascular & Metabolic Diseases sales represented 38% of
Total Product Sales.
Brilinta (full-year sales of $839m; up by 39%)
Sales of Brilinta in the US were $348m, representing an increase
of 45%. The performance reflected updated preferred guidelines from
the American College of Cardiology and the American Heart
Association in the first half of the year; Brilinta remained the
branded oral anti-platelet market leader in the US. Brilinta's
new-to-brand weekly prescription market share jumped to around 15%
at the end of the year, representing an increase of around three
percentage points.
Full-year sales of Brilique in Europe increased by 15% to $258m,
reflecting indication leadership across a number of markets. In the
year, the German Institute for Quality and Efficiency in Healthcare
(IQWiG) gave its assessment of the additional benefit from Brilique
at the 60mg dose as tested in the PEGASUS trial, as did the
National Institute for Health and Clinical Excellence in England,
UK.
Emerging Markets full-year sales grew by 80% to $189m, with
China sales more than doubling. China represented 47% of Emerging
Markets sales of the medicine at $89m, despite it not being
included on the National Reimbursement Drug List. The Company
anticipates inclusion in due course. Growth was underpinned by a
combination of strong levels of hospital-listing expansion and
increased use in existing hospitals.
Farxiga (full-year sales of $835m; up by 72%)
In the year, sales of Farxiga surpassed those of Onglyza and
Farxiga became the leading AstraZeneca medicine for the treatment
of diabetes, consolidating its position as global leader in the
SGLT2 class.
Sales of Farxiga in the US increased by 75% to $457m, primarily
reflecting overall market growth and a higher net price. A stronger
emphasis on promotional activity and improved levels of patient
access resulted in market-share growth. Full-year sales of Forxiga
in Europe increased by 52% to $187m, as the medicine continued to
lead the growing class. Emerging Markets sales increased by 96% to
$133m, driven by ongoing launches and improved access. In
particular, strong performances were seen in the Asia-Pacific
region (up by 108% to $52m), Brazil (up by 50% to $28m), and the
Middle East, Africa & Others region (up to $32m).
Onglyza (full-year sales of $720m; down by 6%)
Sales in the US declined by 10% to $376m, as the Company
prioritised sales and marketing resources towards Farxiga.
Continued competitive pressures in the DPP-4 class led to lower
market share but were partially offset by reduced levels of
utilisation of patient-access programmes. Full-year sales in Europe
declined by 5% to $132m and by 4% in Emerging Markets to $142m,
again reflecting the Company's focus on Farxiga.
In the quarter, global sales declined by 21%, due to adverse
pressures on the DPP-4 class and reflecting an acceleration of the
previously-mentioned market dynamics.
Bydureon/Byetta (full-year sales of $832m; down by 7%)
Combined full-year US sales for Bydureon/Byetta were $627m.
Bydureon sales in the US declined by 4% to $463m, representing 74%
of total Bydureon/Byetta US sales. Around 75% of sales came from
the new dual-chamber pen compared to the prior tray presentation.
The decline in US Byetta sales of 22% to $164m was attributed to
the Company's promotional focus on Bydureon. The decline in both
Bydureon and Byetta US sales reflected lower net pricing; a
regulatory submission for the new Bydureon autoinjector is
anticipated in the US in the first half of 2017.
Full-year sales in Europe increased by 3% to $145m, reflecting
the Company's ongoing effort to expand its Diabetes presence.
Full-year sales of Byetta and Bydureon in Emerging Markets
increased by 13% to $24m and decreased by 25% to $4m, respectively.
On 10 October 2016, AstraZeneca entered into a strategic
collaboration with 3SBio Inc. (3SBio) for the rights to
commercialise Bydureon and Byetta in the Chinese market. The
agreement allowed the Company to benefit from 3SBio's established
local expertise in injectable medicines as well as focus on its
oral type-2 diabetes medicines.
Legacy: Crestor (full-year sales of $3,401m; down by 32%)
In the US, Crestor full-year sales declined by 57% to $1,223m,
reflecting the market entry of Crestor generic medicines. Sales in
the quarter declined by 88% to $95m. In Europe, full-year sales
declined by 4% to $866m, reflecting the increasing use of generic
medicines. In contrast, Crestor consolidated its position as the
leading statin in Japan, with full-year sales stable at $521m.
Full-year sales in China grew by 27% to $311m, while Russia sales
grew by 28% to $29m.
RESPIRATORY
Full-year sales of $4,753m; down by 3%.
Respiratory sales represented 22% of Total Product Sales.
Symbicort (full-year sales of $2,989m; down by 10%)
Full-year sales in the US declined by 18% to $1,242m. This
primarily reflected the impact of the continued effects of pricing
pressure from managed-care access within the ICS/LABA class.
Competition also remained intense from other classes. In Europe,
full-year sales declined by 12% to $909m, primarily a result of
competition from branded and analogue medicines. The performance
improved during the year, with Q4 2016 sales in Europe declining by
only 3% to $230m.
In contrast, full-year Emerging Markets sales grew by 10% to
$402m, reflecting sales growth in China of 32% to $156m and Latin
America (ex-Brazil) sales growth of 12% to $37m.
Symbicort continued to lead the global market by volume within
the class; the medicine provides a platform for the launch of
Bevespi and potential launch of benralizumab.
Pulmicort (full-year sales of $1,061m; up by 8%)
Pulmicort returned to being a blockbuster medicine in the
year.
Strong underlying volume growth in Emerging Markets drove a 21%
sales increase in that region to $698m. Emerging Markets,
representing 66% of Pulmicort sales, more than offset sales
declines in the US, Europe and Established ROW. China sales
increased by 24% to $570m and represented 54% of sales of
Pulmicort. Volume demand in China partly reflected the long-term
increase in China of acute chronic obstructive pulmonary disease
(COPD) and paediatric asthma. AstraZeneca continued its expansion
of treatment centres and provided increased access to home-based
patient-care systems.
Tudorza/Eklira (full-year sales of $170m; down by 9%)
Sales in the US declined by 25% to $77m, reflecting adverse
market demand, limited Medicare Part D access and the focus on the
launch of Bevespi. Sales in Europe increased by 9% to $83m.
Daliresp/Daxas (full-year sales of $154m; up by 48%)
Sales in the US increased by 29% to $134m in the year, driven
primarily by favourable market penetration. US sales represented
87% of global sales. ROW sales rights were added in May 2016 and,
since completion, Daxas sales in Europe amounted to $15m.
Duaklir (full-year sales of $63m)
Duaklir has been launched successfully in excess of 25
countries; sales more than doubled in the year. This followed the
strategic transaction with Almirall, S.A., which was completed in
October 2014.
Bevespi
Bevespi Aerosphere inhalation aerosol was launched commercially
in the US in January 2017 and is available in pharmacies for the
long-term, maintenance treatment of airflow obstruction in patients
with COPD. It is the only LAMA/LABA combination treatment to be
delivered in a pressurised metered-dose inhaler (pMDI) and the
first FDA-approved therapy to be formulated with AstraZeneca's
co-suspension delivery technology, a focus of the Company's
future-platform development for respiratory-disease combination
therapies. Bevespi also demonstrated a 381mL improvement in peak
inspiratory capacity, a potentially differentiating factor.
OTHER
Full-year sales of $5,067m; down by 19%.
Other sales represented 24% of Total Product Sales.
Nexium (full-year sales of $2,032m; down by 18%)
Sales in the US declined by 39% to $554m in the year, reflecting
lower demand and inventory de-stocking, which followed the loss of
exclusivity in 2015. Sales in Europe declined by 11% to $251m, and
Emerging Markets sales decreased 3% to $690m. Japan sales declined
by 4% to $436m, reflecting the mandated biennial price reduction,
effective from April 2016.
Seroquel XR (full-year sales of $735m; down by 27%)
Sales of Seroquel XR in the US declined by 28% to $515m in the
year (Q4 2016: Down by 60% to $71m). Since 1 November 2016, two
companies have launched generic medicines in the US. Full-year
sales of Seroquel XR in Europe declined by 32% to $134m reflecting
the impact of generic-medicine competition.
Synagis (full-year sales of $677m; up by 2%)
Sales in the US increased by 14% to $325m for the full year due
to greater market demand. Sales to AbbVie Inc., which is
responsible for the commercialisation of Synagis in over 80
countries outside the US, declined by 7% to $352m.
FluMist/Fluenz (full-year sales of $104m; down by 59%)
The Company confirmed on 23 June 2016 that the Advisory
Committee on Immunization Practices (ACIP) of the US Centers for
Disease Control and Prevention had provided its interim
recommendation not to use FluMist Quadrivalent Live Attenuated
Influenza Vaccine (FluMist Quadrivalent) in the US for the
2016-2017 influenza season.
The Company wrote down the value of its inventory of FluMist by
$47m in the year, which was reflected within the Cost of Sales.
Full-year sales of FluMist in the US declined by 84% to $33m.
Europe sales increased by 3% in the year to $64m.
Regional Product Sales
_______________________________________________________________________________________
FY 2016 Q4 2016
------------------------------------ ----------------------
$m % of Total % change $m % change
------- ----------- ------
CER Actual CER Actual
------------------------------ ------- ----------- ----- ------- ------ ----- -------
US 7,365 35 (22) (22) 1,618 (37) (37)
Europe 5,064 24 (3) (5) 1,332 (3) (6)
Established ROW(1) 3,096 15 (4) 2 824 (6) 5
Japan 2,184 10 (3) 8 591 (5) 9
Canada 497 2 (2) (7) 126 (5) (6)
Other Established ROW 415 2 (10) (12) 107 (10) (4)
Emerging Markets(2) 5,794 27 6 - 1,486 7 4
China 2,636 12 10 4 609 8 2
Ex. China 3,158 15 3 (4) 877 6 5
Total 21,319 100 (8) (10) 5,260 (15) (15)
------------------------------ ------- ----------- ----- ------- ------ ----- -------
(1) Established ROW comprises Japan, Canada, Australia and New
Zealand.
(2) Emerging Markets comprises all remaining Rest of World
markets, including Brazil, China, India, Mexico, Russia and
Turkey.
US (full-year sales of $7,365m; down by 22%)
The full-year decline in US sales reflected the competition from
Crestor generic medicines that entered the US market from July
2016. Unfavourable managed-care pricing and continued competitive
intensity also impacted sales of Symbicort.
Europe (full-year sales of $5,064m; down by 3%)
Strong growth in sales of Forxiga (up by 52% to $187m) and
Brilique (up by 15% to $258m) was more than offset by a 12% decline
in Symbicort sales to $909m. However, Symbicort maintained its
position as the number one ICS/LABA medicine by volume, despite
competition from branded and analogue medicines. Lynparza and
Tagrisso sales increased to $81m and $76m respectively.
Established ROW (full-year sales of $3,096m; down by 4%)
Full-year sales of Forxiga in Established ROW increased by 72%
to $58m. Nexium sales declined by 10% to $537m.
Japan sales declined by 3% to $2,184m, reflecting the biennial
price reduction, effective from April 2016, of around 6%. The
decline was partly mitigated by stable sales of Crestor of $521m in
the year. Since the launch of Tagrisso in Japan in May 2016, sales
amounted to $82m.
Emerging Markets (full-year sales of $5,794m; up by 6%)
Emerging Markets, representing 27% of global Product Sales, is
the second-largest sales region for AstraZeneca.
Sales growth for the year in Emerging Markets was impacted by
challenging macro-economic conditions in Latin America, where
ex-Brazil full-year sales declined by 7% to $516m. The effect of
reductions in Saudi Arabian governmental healthcare spending, as
well as the reduction of AstraZeneca's activities in Venezuela,
also adversely impacted sales. China sales, however, grew by 10% to
$2,636m, representing 45% of Emerging Markets sales in the
year.
Sales in Brazil increased by 2% to $348m, reflecting the strong
performances of Forxiga (up by 50% to $28m), Oncology medicines (up
by 1% to $82m) and Seloken (up by 6% to $63m). Russia sales
increased by 13% to $233m, led by strong performances in
Cardiovascular & Metabolic Diseases medicine sales (up by 38%
to $80m).
A number of AstraZeneca medicines were externalised or disposed
of in the year, adversely impacting the level of Product Sales:
Medicine Region Externalisation / Disposal Completion Date FY 2015
Impacted Region
Product Sales ($m)
------------------- ------------------- -------------------------------------------- --------------------
Bydureon & Byetta China 11 October 2016 15
Anaesthetics Global (excl. US) 1 September 2016 594
Plendil China 29 February 2016 189
Moventig Europe 1 March 2016 1
Toprol-XL US 31 October 2016 89
Imdur Global (excl. US) 3 May 2016 55
Total 943
-------------------------------------------------------------------------------------- --------------------
Financial Performance
______________________________________________________________________________________
Year Reported % change Core % change
-------------------------- ----------------- ------------ ---------------- ------------
FY FY CER Actual FY 2016 FY CER Actual
2016 2015 2015
-------------------------- ------- ------- ------- ---- ------
Product Sales 21,319 23,641 (8) (10) 21,319 23,641 (8) (10)
Externalisation Revenue 1,683 1,067 59 58 1,683 1,067 59 58
Total Revenue 23,002 24,708 (5) (7) 23,002 24,708 (5) (7)
Cost of Sales (4,126) (4,646) (7) (11) (3,872) (4,119) (2) (6)
Gross Profit 18,876 20,062 (5) (6) 19,130 20,589 (6) (7)
Gross Margin(1) 80.8% 80.3% -0.1 +0.5 82.0% 82.6% -1.1 -0.6
Distribution Expense (326) (339) 1 (4) (326) (339) 1 (4)
% Total Revenue 1.4% 1.4% - - 1.4% 1.4% - -
R&D Expense (5,890) (5,997) 2 (2) (5,631) (5,603) 5 -
% Total Revenue 25.6% 24.3% -2 -1 24.5% 22.7% -2 -2
SG&A Expense (9,413) (11,112) (12) (15) (8,169) (9,265) (9) (12)
% Total Revenue 40.9% 45.0% +3 +4 35.5% 37.5% +1 +2
Other Operating Income 1,655 1,500 12 10 1,717 1,520 14 13
% Total Revenue 7.2% 6.1% +1 +1 7.5% 6.2% +1 +1
Operating Profit 4,902 4,114 9 19 6,721 6,902 (7) (3)
% Total Revenue 21.3% 16.7% +3 +5 29.2% 27.9% - +1
Net Finance Expense (1,317) (1,029) 37 28 (661) (505) 46 31
Joint Ventures (33) (16) (33) (16)
Profit Before Tax 3,552 3,069 - 16 6,027 6,381 (11) (6)
Taxation (146) (243) (658) (990)
Tax Rate % 4% 8% 11% 16%
Profit After Tax 3,406 2,826 6 21 5,369 5,391 (6) -
Non-controlling Interests 93 (1) 86 (1)
Net Profit 3,499 2,825 9 24 5,455 5,390 (5) 1
Weighted Average Shares 1,265 1,264 1,265 1,264
Earnings Per Share ($) 2.77 2.23 9 24 4.31 4.26 (5) 1
-------------------------- ------- -------- ---- ------ ------- ------- ---- ------
(1) Gross Margin reflects Gross Profit derived from Product
Sales, divided by Product Sales
(2) All financial figures, except Earnings Per Share, are in $
millions ($m). Weighted Average Shares are in millions.
Quarter Reported % change Core % change
-------------------------- ---------------- ------------ ---------------- ------------
Q4 2016 Q4 CER Actual Q4 Q4 2015 CER Actual
2015 2016
-------------------------- ------- ------- ------- ---- ------
Product Sales 5,260 6,207 (15) (15) 5,260 6,207 (15) (15)
Externalisation Revenue 325 192 77 69 325 192 77 69
Total Revenue 5,585 6,399 (12) (13) 5,585 6,399 (12) (13)
Cost of Sales (1,160) (1,269) (2) (9) (1,087) (1,209) (4) (10)
Gross Profit 4,425 5,130 (15) (14) 4,498 5,190 (14) (13)
Gross Margin(1) 77.9% 79.6% -3.1 -1.7 79.3% 80.5% -2.6 -1.2
Distribution Expense (83) (99) (11) (16) (83) (99) (11) (16)
% Total Revenue 1.5% 1.5% - - 1.5% 1.5% - -
R&D Expense (1,543) (1,746) (5) (12) (1,481) (1,567) 2 (5)
% Total Revenue 27.6% 27.3% -2 - 26.5% 24.5% -4 -2
SG&A Expense (1,386) (2,668) (44) (48) (2,050) (2,461) (14) (17)
% Total Revenue 24.8% 41.7% +15 +17 36.7% 38.5% +1 +2
Other Operating Income 1,120 471 n/m n/m 1,142 493 n/m n/m
% Total Revenue 20.1% 7.4% +13 +13 20.4% 7.7% +13 +13
Operating Profit 2,533 1,088 n/m n/m 2,026 1,556 15 30
% Total Revenue 45.4% 17.0% +23 +28 36.3% 24.3% +8 +12
-.
Net Finance Expense (339) (279) 36 22 (172) (150) 36 15
Joint Ventures (11) (7) (11) (7)
Profit Before Tax 2,183 802 n/m n/m 1,843 1,399 13 32
Taxation (366) 6 (333) (200)
Tax Rate % 17% (1)% 18% 14%
Profit After Tax 1,817 808 91 n/m 1,510 1,199 7 26
Non-controlling Interests 25 - 23 -
Net Profit 1,842 808 94 n/m 1,533 1,199 9 28
Weighted Average Shares 1,265 1,264 1,265 1,264
Earnings Per Share ($) 1.46 0.63 93 n/m 1.21 0.94 9 29
-------------------------- ------- ------- ---- ------ ------- ------- ---- ------
(1) Gross Margin reflects Gross Profit derived from Product
Sales, divided by Product Sales
(2) All financial figures, except Earnings Per Share, are in $
millions ($m). Weighted Average Shares are in millions
Reconciliation Of Reported To Core Performance
FY 2016 Reported Restructuring Intangible Asset Diabetes Alliance Other(1) Core
Amortisation & Impairments
--------------------------
$m $m $m $m $m $m
-------------------------- -------- ------------- --------------------------- ----------------- -------- -------
Cost of Sales (4,126) 130 124 - - (3,872)
R&D Expense (5,890) 178 81 - - (5,631)
SG&A Expense (9,413) 823 1,000 (627) 48 (8,169)
Other Operating Income 1,655 (24) 86 - - 1,717
Net Finance Expense (1,317) - - 389 267 (661)
Taxation (146) (232) (307) 23 4 (658)
Non-controlling Interests 93 (7) - - - 86
-------------------------- -------- ------------- --------------------------- ----------------- -------- -------
Total 868 984 (215) 319
-------------------------- -------- ------------- --------------------------- ----------------- -------- -------
Q4 2016 Reported Restructuring Intangible Asset Diabetes Alliance Other(1) Core
Amortisation & Impairments
--------------------------
$m $m $m $m $m $m
-------------------------- -------- ------------- --------------------------- ----------------- -------- -------
Cost of Sales (1,160) 43 30 - - (1,087)
R&D Expense (1,543) 32 30 - - (1,481)
SG&A Expense (1,386) 319 246 (938) (291) (2,050)
Other Operating Income 1,120 - 22 - - 1,142
Net Finance Expense (339) - - 97 70 (172)
Taxation (366) (82) (86) 162 39 (333)
Non-controlling Interests 25 (2) - - - 23
-------------------------- -------- ------------- --------------------------- ----------------- -------- -------
Total 310 242 (679) (182)
-------------------------- -------- ------------- --------------------------- ----------------- -------- -------
(1) Other adjustments include provision charges related to
certain legal matters (see Note 7) and fair-value adjustments
arising on acquisition-related liabilities (see Note 6).
Profit And Loss Commentary
Gross Profit
Reported Gross Profit declined by 5% in the year to $18,876m
reflecting the market entry of Crestor generic medicines in the US.
Excluding the impact of Externalisation Revenue, the Reported Gross
Profit Margin was broadly stable at 80.8%, with lower restructuring
and amortisation charges offset by an adverse impact from the mix
of sales and a write-down of FluMist inventory in the US. Excluding
these lower restructuring and amortisation charges, Core Gross
Profit declined by 6% in the year to $19,130m and, excluding the
impact of externalisation, the Core Gross Profit margin declined by
one percentage point to 82.0%.
In the quarter, Reported Gross Profit declined by 15% to $4,425m
and Reported Gross Margin declined by three percentage points to
77.9%. Excluding restructuring and amortisation charges, Core Gross
Profit declined by 14% to $4,498m and the Core Gross Margin
declined by three percentage points to 79.3%.
Operating Expenses: R&D
Reported R&D costs increased by 2% in the year to $5,890m
(Q4 2016: $1,543m, a decline of 5%). The full-year increase
reflected the number of potential new medicines in pivotal trials
as well as the absorption of the R&D costs of ZS Pharma and
Acerta Pharma. These costs were partially offset by lower
restructuring costs and impairment charges. Without the impact of
ZS Pharma and Acerta Pharma, Reported R&D costs in the year
would have declined by 3%.
Excluding the impact of lower restructuring and impairment
charges, Core R&D costs increased by 5% in the year to $5,631m
(Q4 2016: $1,481m, an increase of 2%). Without the impact of the
previously-mentioned investments in ZS Pharma and Acerta Pharma,
Core R&D costs in the year would have declined by 1%. This
compares to the 21% increase in Core R&D costs in FY 2015.
Operating Expenses: SG&A
Reported SG&A costs declined by 12% in the year to $9,413m,
reflecting the evolving shape of the business. The decline was also
driven by efficiency savings in sales and marketing operations and
further reductions in IT costs. These actions included a material
reduction in the sales and head-office structure in the US
marketing business. Reported SG&A costs declined by 44% in the
quarter to $1,386m, reflecting the fair-value adjustment to
acquisition-related liabilities.
Core SG&A costs declined by 9% in the year to $8,169m, in
line with full-year expectations of a material reduction. Core
SG&A costs declined by 14% in the quarter to $2,050m.
Other Operating Income
Where AstraZeneca does not retain a significant economic
interest in medicines or potential new medicines, income from
transactions is reported as Other Operating Income in the Company's
financial statements.
Reported Other Operating Income of $1,655m in the year
included:
$m
----------------------------------------------------------- ---------------------------------------------------------
Sale of the small-molecule antibiotics business to Pfizer 368
net of carrying values disposed and other costs to sell
Sale of the ex-US rights to Rhinocort Aqua to Cilag GmbH
International (Cilag) 321
Sale of ex-US rights of Imdur 183
Crestor royalties 165
Out-licensing of a potential medicine (MEDI2070) for 148
inflammatory diseases to Allergan plc net, reflecting an agreement with Amgen Inc. (Amgen)
(Allergan)
HPV royalties 134
Other 336
----------------------------------------------------------- ---------------------------------------------------------
Total 1,655
----------------------------------------------------------- ---------------------------------------------------------
Operating Profit
Reported Operating Profit increased by 9% in the year to
$4,902m. The Reported Operating Margin increased by three
percentage points to 21% of Total Revenue.
Core Operating Profit declined by 7% in the year to $6,721m. The
Core Operating Margin was stable at 29% of Total Revenue.
Net Finance Expense
Reported Net Finance Expense increased by 37% in the year to
$1,317m, reflecting an increase in Net Debt that was driven by the
acquisition of ZS Pharma and the majority investment in Acerta
Pharma. Excluding the discount unwind on acquisition-related
liabilities, Core Net Finance Expense increased by 46% in the year
to $661m.
Taxation
Excluding a one-off benefit of $453m following agreements
between the Canadian tax authority and the UK and Swedish tax
authorities in respect of transfer pricing arrangements for the
13-year period from 2004-2016, the Reported and Core tax rates for
the year were 17% and 18% respectively. Including the impact of
this benefit, the Reported and Core tax rates for the year were 4%
and 11% respectively. The cash tax paid for the year was $412m,
which was 12% of Reported Profit Before Tax and 7% of Core Profit
Before Tax.
The Reported and Core tax rates in FY 2015 were 22% and 21%
respectively when excluding a one-off tax benefit of $186m
following the agreement of US federal tax liabilities of open years
up to 2008, other provision releases and the benefit of the UK
patent box. Including the impact of these benefits, the Reported
and Core tax rates in FY 2015 were 8% and 16% respectively.
Earnings Per Share (EPS)
Reported EPS of $2.77 in the year represented growth of 9%; this
included a gain of $0.76 on the revaluation of acquisition-related
liabilities. Core EPS in the year declined by 5% to $4.31, driven
by the same rate of decline in Total Revenue. Both Reported and
Core EPS in the year included a non-recurring benefit of $0.36,
following the previously-mentioned agreements between the Canadian
tax authority and the UK and Swedish tax authorities.
Dividends
The Board has declared a second interim dividend of $1.90 per
share (150.2 pence, 16.57 SEK) bringing the dividend per share for
the full year to $2.80 (218.9 pence, 24.38 SEK). The Board
reaffirms its commitment to the Company's progressive dividend
policy.
For holders of the Company's American Depositary Shares (ADSs),
the $1.90 per Ordinary Share equates to $0.95 per ADS. Two ADSs
equal one Ordinary Share.
Productivity
AstraZeneca's evolution and the changing shape of the business
have enabled productivity improvements through the implementation
of restructuring initiatives. These included those announced on 29
April 2016. Restructuring charges of $1,107m were incurred in the
year. The Company remains on track to realise benefits and incur
costs in line with prior announcements.
Cash Flow And Balance Sheet
Cash Flow
The Company generated a net cash inflow from operating
activities of $4,145m in the year, compared with $3,324m in the
comparative period. The increase reflected improved cash management
performance and one-off tax refunds.
Net cash outflows from investing activities were $3,969m
compared with $4,239m in the comparative period. The outflows
partly reflected the net cash outflow of $2,383m in relation to the
majority investment in Acerta Pharma, as well as $1,446m for the
purchase of property, plant and equipment.
Net cash outflows from financing activities were $1,324m,
incorporating $2,491m of new long-term loans, net of dividend
payments in the year of $3,561m. This compared to an inflow of
$878m in the comparative period.
The cash payment of contingent consideration in respect of the
Bristol-Myers Squibb Company share of the global Diabetes alliance
amounted to $242m in the year. The consideration is based on a
tiered structure, whereby a higher royalty rate is applied until a
specified level of sales is achieved in the year; thereafter a
lower rate is applied to the remaining sales in the year and
settled in the quarter following the application of the charge.
From FY 2017 a single annual rate will be applied.
Capital Expenditure
Capital expenditure amounted to $1,449m in the year,
representing an increase of 3%; the majority of capital expenditure
was in maintenance. Investment in AstraZeneca's return to growth
continued, with an element of capital expenditure split between
expansion of biologics manufacturing capacity and the impending
completion of the R&D centre and global headquarters in
Cambridge, UK.
Debt and Capital Structure
At 31 December 2016, outstanding gross debt (interest-bearing
loans and borrowings) was $16,808m
(31 December 2015: $15,053m). Of the gross debt outstanding at
31 December 2016, $2,307m was due within one year (31 December
2015: $916m). The Company's net debt position at 31 December 2016
was $10,657m (31 December 2015: $7,762m).
Shares in Issue
During the year, 1.1 million shares were issued in respect of
share option exercises for consideration of $47m. The total number
of shares in issue as at 31 December 2016 was 1,265 million.
Capital Allocation
The Board's aim is to continue to strike a balance between the
interests of the business, financial creditors and the Company's
shareholders. After providing for investment in the business,
supporting the progressive dividend policy and maintaining a
strong, investment-grade credit rating, the Board will keep under
review potential investment in immediately earnings-accretive,
value-enhancing opportunities. The Board reconfirms the continued
suspension of the share repurchase programme.
Sensitivity: Foreign-Exchange Rates
The Company provides the following currency sensitivity
information:
Average Impact Of 5% Strengthening In
Exchange Exchange Rate Versus USD
Rates ($m)(2)
Versus USD
----------- ----------- ------------------------------
Currency Primary FY 2016 YTD 2017(1) change % Total Core Operating
Relevance Revenue Profit
----------- ------------- ----------- ----------- --------- ------------ ----------------
EUR Product Sales 0.90 0.94 -4% +179 +123
JPY Product Sales 108.84 115.14 -5% +104 +71
CNY Product Sales 6.65 6.87 -3% +131 +74
SEK Costs 8.56 8.97 -5% +7 -98
GBP Costs 0.74 0.81 -9% +29 -131
Other(3) +194 +124
(1) Based on average daily spot rates between 1st January and 30th January 2017
(2) Based on 2016 actual results at 2016 actual exchange rates
(3) Other important currencies include AUD, BRL, CAD, KRW and RUB
Currency Hedging
AstraZeneca monitors the impact of adverse currency movements on
a portfolio basis, recognising correlation effects. The Company may
hedge to protect against adverse impacts on cash flow over the
short to medium term. As at 31 December 2016, AstraZeneca had
hedged 96% of forecast short-term currency exposure that arises
between the booking and settlement dates on Product Sales and
non-local currency purchases.
Corporate And Business Development Update
______________________________________________________________________________________
The highlights of the Company's corporate and business
development activities since the prior results announcement are
shown below:
a) Sale Of Small-Molecule Antibiotics Business
On 24 August 2016, the Company announced that it had entered
into an agreement with Pfizer to sell the commercialisation and
development rights to its small-molecule antibiotics business and
late-stage pipeline in most markets outside the US. The transaction
closed in the quarter. As AstraZeneca will not maintain a
significant ongoing interest in the late-stage, small-molecule
antibiotics business, all payments were and will be reported as
Other Operating Income in the Company's financial statements. This
includes the upfront payment of $550m and an unconditional payment
of $175m in 2019 (both recognised net of the carrying value of
assets disposed and other costs to sell in 2016). The future
payments include the milestones of up to $250m, sales-related
payments of up to $600m and recurring double-digit royalties on
sales of Zavicefta and ATM AVI.
b) Sale Of Respiratory Medicine Rhinocort Aqua (Nasal Spray)
On 7 October 2016, the Company announced that it had entered an
agreement with Cilag, an affiliate of Johnson & Johnson, for
the divestment of the rights to Rhinocort Aqua outside the US. The
transaction closed in the quarter.
c) Externalisation Of Beta-Blocker Medicine Toprol-XL
On 31 October 2016, the Company completed an agreement with
Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez
Pharmaceuticals Inc., for the rights to branded and authorised
generic Toprol-XL (metoprolol succinate) in the US. AstraZeneca
will retain a significant ongoing interest in Toprol-XL through
retained ownership of the medicine in ROW markets and product
supply to Aralez. Therefore, the upfront payment of $175m,
milestones and sales-related payments of up to $48m and mid-teen
percentage royalties was and will be reported as Externalisation
Revenue in the Company's financial statements.
d) Licensing Agreement: Monoclonal Antibody MEDI2070 (Crohn's
Disease)
On 3 October 2016, the Company announced that MedImmune, its
global biologics research and development arm, had entered a
licensing agreement with Allergan for the global rights to MEDI2070
(moderate-to-severe Crohn's disease). The transaction closed in the
quarter. AstraZeneca retained $148m of the upfront payment and will
retain up to approximately $847m in future potential milestones, as
well as the tiered royalty payments of up to low double-digit
percent, following payment to Amgen under the provisions of the
original agreement.
e) Externalisation Of Diabetes Medicines Bydureon And Byetta In
China
On 10 October 2016, AstraZeneca entered a strategic
collaboration with 3SBio for the rights to commercialise Bydureon
and Byetta in the Chinese market. The agreement allowed the Company
to benefit from 3SBio's established expertise in injectable
medicines and also focus resources on AstraZeneca's oral diabetes
franchise, including Onglyza, which is already marketed in China,
as well as Forxiga and Kombiglyze, which are anticipated to launch
in China in 2017. The transaction closed in the quarter.
Under the terms of the collaboration agreement, 3SBio made an
upfront payment of $50m and will pay development milestones of up
to a further $50m for the exclusive rights to commercialise
Bydureon and Byetta in the Chinese market (excluding Hong Kong) for
an initial period of 20 years. AstraZeneca will retain a
significant ongoing interest in Bydureon and Byetta through
retained ownership of the medicines in other markets and will
manufacture and supply these medicines to 3SBio for an agreed
purchase price.
f) MEDI1814 (Alzheimer's Disease)
AstraZeneca continues to collaborate with Lilly in the
development of medicines for patients impacted by Alzheimer's
disease (AD). Building on the current collaboration for the BACE
inhibitor, AZD3293, currently in two Phase III trials, the
companies are now also co-developing MEDI1814, an antibody
selective for amyloid-beta 42 (A<BETA>42), which is currently
in Phase I development as a potential disease-modifying treatment
for AD. The build-up of plaque in the brain containing the peptide
amyloid-beta (A<BETA>) is one of the pathological hallmarks
of AD. MEDI1814 binds selectively to A<BETA>42, which is
believed to be a more toxic A<BETA> species. In pre-clinical
models, MEDI1814 dose-dependently reduces levels of this peptide,
potentially slowing the progression of AD.
g) Senior Executive Team Changes
In January 2017, Leon Wang was appointed to the newly-created
SET role of Executive Vice-President, Asia Pacific, with
responsibility for the Company's activities in China and Hong Kong,
Asia Area, Australia and New Zealand. Leon joined AstraZeneca China
in 2013 as a Vice-President and became President in 2014. Under his
leadership China became AstraZeneca's second-largest market
worldwide. Leon has twenty years of experience in the
pharmaceutical industry.
As Executive Vice-President, International West, Mark Mallon
retains responsibility for AstraZeneca's businesses in Russia,
Latin America, and the Middle East and Africa in addition to his
role as EVP, Global Product and Portfolio Strategy, Global Medical
Affairs & Corporate Affairs.
It was announced in January 2017 that Luke Miels, formerly
Executive Vice-President, Europe would leave AstraZeneca to take up
a senior position with a main competitor.
Research and Development Update
______________________________________________________________________________________
A comprehensive table with AstraZeneca's pipeline of medicines
in human trials can be found later in this document.
Since the results announcement on 10 November 2016 (the
period):
Regulatory Submission 8
Acceptances * durvalumab - bladder cancer (US)
* Tagrisso - lung cancer (AURA3 trial) (US, EU)
* Faslodex - breast cancer (1L) (US, EU)
* roxadustat - anaemia (CN) (rolling submission)
* benralizumab - severe, uncontrolled asthma (US, EU)
Other Key Developments 2
* Priority Review Designation: durvalumab (US)
* Priority Review Designation: Tagrisso (US)
New Molecular 12
Entities Oncology
(NMEs) In Phase * durvalumab* - multiple cancers
III Trials
Or Under Regulatory
Review*(#) * durva + treme - multiple cancers
* acalabrutinib - blood cancers
* moxetumomab pasudotox - leukaemia
* selumetinib - thyroid cancer
Cardiovascular & Metabolic Diseases
* ZS-9* - hyperkalaemia
* roxadustat* - anaemia
Respiratory
* benralizumab* - severe, uncontrolled asthma
* tralokinumab - severe, uncontrolled asthma
* PT010 - COPD
Other
* anifrolumab - lupus
* AZD3293 - Alzheimer's disease
------------------------ ---- -----------------------------------------------------------------
Projects in clinical
pipeline(#) 120
------------------------ ---- -----------------------------------------------------------------
(#) As at 2 February 2017
ONCOLOGY
AstraZeneca has a deep-rooted heritage in Oncology and offers a
growing portfolio of new medicines that has the potential to
transform patients' lives and the Company's future. At least six
new Oncology medicines are expected to be launched between 2014 and
2020, of which two have already been launched (Lynparza and
Tagrisso). A broad pipeline of small molecules and biologics is in
development and the Company is committed to advancing Oncology as
one of AstraZeneca's Growth Platforms primarily focused on lung,
ovarian, breast and blood cancers.
In addition to its own existing cancer medicine capabilities,
the Company is actively pursuing innovative collaborations and
investments that are designed to accelerate the delivery of
AstraZeneca's strategy, as illustrated by the Company's majority
investment in Acerta Pharma in haematology that closed in 2016.
At three recent medical meetings, ASH (American Society of
Hematology), WCLC (World Conference on Lung Cancer) and the San
Antonio Breast Cancer Symposium, AstraZeneca highlighted its
continued momentum in Oncology with a total of 50 abstracts,
including 15 oral presentations. Abstracts and presentations
provided a comprehensive update on recent data from Faslodex,
Iressa, Tagrisso and the Company's emerging presence in blood
cancers, through acalabrutinib.
a) Faslodex (breast cancer)
During the period, the Company received regulatory submission
acceptances for Faslodex in 1st-line metastatic breast cancer in
the US and the EU. The submissions were based on the Phase III
FALCON trial that compared Faslodex 500mg to Arimidex 1mg for the
treatment of locally-advanced or metastatic breast cancer, in
post-menopausal women who have not had prior hormonal treatment for
hormone receptor-positive breast cancer. Faslodex demonstrated
superiority compared with Arimidex and met its primary endpoint of
extended progression-free survival (PFS).
b) Tagrisso (lung cancer)
In December 2016, data from the AURA3 trial were presented at
WCLC. AURA3 was the first randomised and controlled trial for
Tagrisso and tested the medicine in 2nd-line treatment of patients
with epidermal growth factor receptor (EGFR) T790M
mutation-positive locally-advanced or metastatic NSCLC against
standard-of-care (SoC) platinum-based doublet chemotherapy. The
trial showed that Tagrisso significantly improved PFS by 5.7 months
with a hazard ratio of 0.30 (equal to a risk reduction of 70%).
Additionally, in the 34% of patients with central nervous system
(CNS) metastases at baseline, PFS was also significantly greater
(4.3 months, hazard ratio 0.32) with Tagrisso. The medicine's
ability to provide benefit in patients with CNS metastases is
encouraging and Tagrisso continues to be tested in the BLOOM trial.
Based on results from AURA3, regulatory submissions were made in
the US and EU during the period; acceptances were received on both
submissions and Priority Review Designation was obtained in the
US.
c) Durvalumab (multiple cancers)
In December 2016, AstraZeneca received FDA acceptance with
Priority Review status of the Biologics License Application (BLA)
for durvalumab in patients with locally-advanced or metastatic
urothelial carcinoma, whose disease has progressed during or after
one standard platinum-based regimen. This acceptance was based on
the results of the urothelial cancer cohort of Study 1108 and
follows the FDA's Breakthrough Therapy Designation for durvalumab
in bladder cancer in February 2016. The Prescription Drug User Fee
Act (PDUFA) date is in the second quarter of 2017.
The Company is also advancing durvalumab alone and in
combination with tremelimumab in bladder cancer.
METASTATIC UROTHELIAL BLADDER CANCER
----------------------------------------------------------------------------------------
Name Phase Line of Population Design Timelines Status
Treatment
------- ------ -------------- -------------- ------------- -------------- --------
Combination therapy
----------------------------------------------------------------------------------------
DANUBE III 1st Line Cisplatin durvalumab, FPD(1) Q4 Ongoing
chemo- durva + 2015
therapy- treme vs SoC
eligible/ chemotherapy
ineligible First data
bladder anticipated
cancer 2018
------- ------ -------------- -------------- ------------- -------------- --------
The Company continues to advance multiple monotherapy trials of durvalumab and combination
trials of durvalumab with tremelimumab and other potential new medicines in Immuno-Oncology
(IO). An update on key AstraZeneca-sponsored ongoing trials with durvalumab outside bladder
cancer is provided below:
LUNG CANCER
-------------------------------------------------------------------------------------------
Name Phase Line of Population Design Timelines Status
Treatment
------------ ------ ---------- ------------- -------------- ------------ ------------
Monotherapy
-------------------------------------------------------------------------------------------
ADJUVANT(2) III N/A Stage durvalumab vs FPD Q1 2015 Ongoing
Ib-IIIa placebo
NSCLC First data
anticipated
2020
------------ ------ ---------- ------------- -------------- ------------ ------------
PACIFIC III N/A Stage III durvalumab vs FPD Q2 2014 Recruitment
unresectable placebo completed
NSCLC LPCD(3) Q2
2016
First data
anticipated
H2 2017
------------ ------ ---------- ------------- -------------- ------------ ------------
PEARL III 1st line NSCLC (Asia) durvalumab vs First data Initiating
SoC anticipated
chemotherapy 2020
------------ ------ ---------- ------------- -------------- ------------ ------------
Combination therapy
-------------------------------------------------------------------------------------------
MYSTIC III 1st line NSCLC durvalumab, FPD Q3 2015 Recruitment
durva + treme completed
vs SoC LPCD Q3
chemotherapy 2016
First data
anticipated
mid-2017
------------ ------ ---------- ------------- -------------- ------------ ------------
NEPTUNE III 1st line NSCLC durva + treme FPD Q4 2015 Ongoing
vs SoC
chemotherapy First data
anticipated
2018
------------ ------ ---------- ------------- -------------- ------------ ------------
- III 1st line NSCLC durvalumab + - Ongoing in
chemotherapy safety
+/- lead-in
tremelimumab Phase I/II
trial
------------ ------ ---------- ------------- -------------- ------------ ------------
ARCTIC III 3rd line PD-L1 neg. durvalumab, FPD Q2 2015 Recruitment
NSCLC tremelimumab, completed
durva + treme LPCD Q3
vs SoC 2016
chemotherapy
First data
anticipated
H1 2017
------------ ------ ---------- ------------- -------------- ------------ ------------
CASPIAN III 1st line Small-cell durvalumab + - Initiating
lung cancer SoC, durva +
treme + SoC
vs SoC
chemotherapy
------------ ------ ---------- ------------- -------------- ------------ ------------
(1) FPD = First Patient Dosed
(2) Conducted by the National Cancer Institute of Canada
(3) LPCD = Last Patient Commenced Dosing
On 17 January 2017, the Company provided an update on its late-stage IO clinical-development
programme in 1st-line NSCLC, including a refinement of the Phase III MYSTIC trial. The trial
was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and
tremelimumab (durva + treme) combination therapy versus SoC chemotherapy, focused on PFS.
The MYSTIC trial will now assess PFS and overall survival (OS) endpoints in patients with
PDL1-expressing tumours for both durvalumab monotherapy and the combination of durva + treme,
as well as in 'all comers' for the combination of durva + treme, versus SoC chemotherapy.
While the focus remains on exploring the benefit of durva + treme as combination therapy,
the Company has updated the endpoints of the MYSTIC trial to include OS and PFS in durvalumab
monotherapy. This is based on recent internal and external data, including durvalumab's strong
efficacy in monotherapy presented at recent medical meetings, as well as significant opportunities
in the competitive landscape.
The estimated primary completion date was updated to reflect both an increase in patient recruitment
(as reported in February 2016 with the inclusion of OS as a co-primary endpoint) and the event-based
nature of the trial. As a result, the Company anticipates MYSTIC PFS data in mid-2017 and
final OS data, at the latest, in 2018. MYSTIC also includes several undisclosed interim analyses
for OS.
Additionally, the ongoing Phase III NEPTUNE trial will be expanded with local patients to
support regulatory submission of durva + treme combination therapy in China for 1st-line NSCLC
patients, without delaying the anticipated OS data readout in 2018 from the global cohort,
which is approaching full recruitment. The Company has also initiated the new Phase III PEARL
trial of durvalumab monotherapy versus SoC chemotherapy in 1st-line NSCLC patients, whose
tumours express PD-L1. The PEARL trial focuses on Asian countries, primarily China, due to
the prevalence of NSCLC in the region.
At WCLC, AstraZeneca presented safety findings from the safety lead-in Phase Ib trial of durvalumab
with or without tremelimumab in combination with doublet chemotherapy. The conclusion of this
trial was that in a
PD-L1 unselected patient population, durvalumab and tremelimumab can be safely combined with
full doses of pemetrexed/cisplatin chemotherapy.
METASTATIC OR RECURRENT HEAD AND NECK CANCER
-----------------------------------------------------------------------------------------
Name Phase Line of Population Design Timelines Status
Treatment
-------- -------- ------------ ----------- -------------- -------------- ----------
Combination therapy
-----------------------------------------------------------------------------------------
KESTREL III 1st line HNSCC* durvalumab, FPD Q4 2015 Ongoing
durva + treme
vs SoC First data
anticipated
H2 2017
---------- ------ ------------ ------------- -------------- -------------- --------
EAGLE III 2nd line HNSCC durvalumab, FPD Q4 2015 Ongoing
durva + treme
vs SoC First data
anticipated
2018
---------- ------ ------------ ------------- -------------- -------------- --------
*Head and Neck Squamous Cell Carcinoma
As communicated on 15 December 2016, the Company has reviewed
data from the CONDOR trial, a randomised, but non-controlled Phase
II trial in 2nd-line PDL1-negative HNSCC patients. While the data
show efficacy and safety of the experimental medicines, AstraZeneca
does not believe that a non-controlled trial can facilitate a
regulatory submission for accelerated approval in a setting where a
PD1-targeted medicine was approved during 2016, based on an OS
benefit in all-comers.
On 22 November 2016, AstraZeneca announced that the FDA had
lifted the partial clinical hold on the enrolment of new patients
with HNSCC for clinical trials of durvalumab as monotherapy and in
combination with tremelimumab or other potential new medicines. The
partial clinical hold on new patient enrolment was communicated on
27 October 2016, after preliminary findings from ongoing clinical
trials related specifically to HNSCC. The FDA lifted the hold
following a review of the comprehensive analysis provided by
AstraZeneca of bleeding events that were observed as part of the
routine safety monitoring of the Phase III KESTREL and EAGLE
trials.
d) Acalabrutinib (blood cancers)
Less than a year after announcing a majority investment in
Acerta Pharma, AstraZeneca provided new clinical data on
acalabrutinib, a highly-selective, potent Bruton tyrosine-kinase
(BTK) inhibitor in Phase III development for B-cell malignancies.
At the 2016 ASH annual meeting, two oral presentations were shared
on acalabrutinib, in patients with Richter's transformation and in
patients with ibrutinib intolerance, both Phase I/II trials.
In patients with Richter's transformation, acalabrutinib
monotherapy produced a partial or complete response in 38% of
patients, with a median time on treatment of 3.4 months. In 21
Richter-transformation patients evaluable for efficacy measures in
the trial, median PFS was 2.1 months and the median duration of
response was 5.2 months. Acalabrutinib monotherapy demonstrated a
tolerable safety profile in patients with Richter's transformation
and these data suggested that further investigation, in combination
with immunotherapy or other targeted therapies, is warranted.
Acalabrutinib was well tolerated in ibrutinib-intolerant
patients, with a total of 12 of 33 (36%) patients experiencing
adverse event (AE) recurrence, most of which reduced or had the
same severity as before; no patients discontinued treatment because
of a recurrent AE. This safety profile was coupled with promising
activity (objective response rate of 79%) and response duration
(81% of responding patients had a duration of response >=12
months).
CARDIOVASCULAR & METABOLIC DISEASES
This therapy area includes a broad type-2 diabetes portfolio,
differentiated devices and unique small and large-molecule
programmes to reduce morbidity, mortality and organ damage across
CV disease, diabetes and chronic kidney disease (CKD)
indications.
a) Bydureon (type-2 diabetes)
During the period, the DURATION-7 trial met its primary endpoint
of a reduction in blood glucose (HbA1c) at 28 weeks as well as key
secondary endpoints. No new safety findings were observed and the
overall rates of AEs and serious AEs were low in both groups.
DURATION-7 was a multi-centre, randomised, double-blind,
placebo-controlled, parallel group, Phase III trial that evaluated
the safety and efficacy of once-weekly Bydureon therapy added to
titrated basal insulin glargine, compared with placebo added to
titrated basal insulin glargine, in patients with type-2 diabetes
who have inadequate glycaemic control on basal insulin glargine
with or without metformin.
b) Type-2 diabetes medicines in CV outcomes trials
As the field of type-2 diabetes medicines evolves, with multiple
outcomes trials producing data, AstraZeneca continues to assess
both Farxiga and Bydureon for potential long-term CV benefits. Two
significant type-2 diabetes outcomes trials are progressing:
Medicine Trial Mode of Number Primary Endpoint Timeline
Action of Patients
--------- -------- ---------------- ------------- ----------------- ------------------
Bydureon EXSCEL GLP-1 agonist 14,000 Time to first Latest 2018
occurrence
of CV death,
non-fatal MI
or non-fatal
stroke
(final analysis)
--------- -------- ---------------- ------------- ----------------- ------------------
Farxiga DECLARE SGLT2 inhibitor 17,000* Time to first Latest 2019
occurrence
of CV death,
non-fatal MI
or non-fatal
stroke
(final analysis)
--------- -------- ---------------- ------------- ----------------- ------------------
*Includes 10,000 patients who have had no prior index event
(primary prevention) and 7,000 patients who have suffered an index
event (secondary prevention).
c) Roxadustat (anaemia)
Roxadustat is a potential first-in-class oral HIF-PH inhibitor
in Phase III development for the treatment of anaemia in CKD
patients. AstraZeneca, FibroGen, Inc. (FibroGen) and Astellas
Pharma Inc. are jointly undertaking an extensive worldwide Phase
III trial programme, enrolling more than 8,000 patients.
In addition to evaluating efficacy, the US/global programme is
designed to demonstrate the CV safety of roxadustat in comparison
to epoetin alfa in dialysis patients (based on data pooled from
four clinical trials) and in comparison to placebo in non-dialysis
patients (based on data pooled from three clinical trials).
AstraZeneca and FibroGen anticipate data readout and US regulatory
submission in 2018.
FibroGen is responsible for development and regulatory
activities in China, and recently announced that the submission
process had initiated and is expected to complete in the second or
third quarter of 2017.
Additionally, on 30 January 2017, FibroGen reported positive
results from two Phase III clinical trials of roxadustat in China.
The two Phase III clinical trials evaluated roxadustat for anaemia
in CKD in patients on dialysis and not on dialysis. Both Phase III
trials met their primary efficacy endpoints, confirming earlier
results. Initial analysis suggests that adverse events were
consistent with previous clinical trials of roxadustat in the CKD
patient population.
RESPIRATORY
AstraZeneca's Respiratory portfolio is aimed at transforming the
treatment of asthma and COPD through combination inhaled therapies,
biologics for the unmet medical needs of specific patient
populations and an early pipeline focused on disease modification.
The growing range of medicines includes up to four launches between
2017 and 2020. The capability in inhalation technology spans both
pMDIs and dry-powder inhalers to serve patient needs, as well as
the innovative Aerosphere co-suspension delivery technology, a
focus of AstraZeneca's future-platform development for
respiratory-disease combination therapies.
a) Symbicort (asthma, COPD)
During the period, the Company received EU approval for
Symbicort SMART (Symbicort Maintenance And Reliever Therapy) for
adolescent asthma patients (aged 12 to <18 years). The SMART
regimen for adolescents is the same as for adult patients, with a
daily maintenance dose of Symbicort Turbuhaler plus additional
doses as needed in response to symptoms. Symbicort SMART is a key
component of the Company's commitment to 'patient-adjusted therapy'
in treating asthma.
On 26 January 2017, AstraZeneca announced that the FDA had
granted six months of paediatric exclusivity for Symbicort, based
on the evaluation of trials conducted in children with asthma aged
six up to 12 years.
b) Benralizumab (severe, uncontrolled asthma)
During the period, AstraZeneca announced that the FDA accepted a
BLA for benralizumab, an anti-eosinophil monoclonal antibody (mAb),
with a PDUFA date anticipated in Q4 2017. The Company also
announced that the European Medicines Agency accepted the Marketing
Authorisation Application (MAA) for benralizumab.
The BLA and MAA submissions, for the treatment of patients with
severe, uncontrolled asthma with an eosinophilic phenotype, were
based on the results of the pivotal Phase III trials, SIROCCO and
CALIMA, that demonstrated that adding benralizumab to SoC
significantly reduced exacerbations and improved lung function and
asthma symptoms. To date, five positive Phase III trials (BISE,
SIROCCO, CALIMA, GREGALE and ZONDA) have supported the efficacy and
safety profile of benralizumab.
ASTRAZENECA DEVELOPMENT PIPELINE 31 DECEMBER 2016
AstraZeneca-sponsored or -directed trials
Phase III / Pivotal Phase II / Registration
New Molecular Entities (NMEs) and significant additional
indications
Regulatory submission dates shown for assets in Phase III and
beyond. As disclosure of compound information is balanced by the
business need to maintain confidentiality, information in relation
to some compounds listed here has not been disclosed at this
time.
Compound Mechanism Area Under Investigation Date Estimated Regulatory Acceptance Date /
Commenced Submission Status
Phase
------------------------- ------------------------- ------------------------------ ---------- -----------------------------------------------------------------------
US EU Japan China
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Oncology
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Tagrisso EGFR inhibitor >=2nd-line advanced EGFRm Launched Launched (Accelerated Launched Accepted
AURA, AURA2, (AURA17 T790M NSCLC (Breakthrough assessment)
Asia regional) Therapy, Priority
Review, Orphan
drug)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Tagrisso EGFR inhibitor >=2nd-line advanced EGFRm Accepted Accepted
AURA3 T790M NSCLC (Priority Review)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) PD-L1 mAb >=2nd-line advanced bladder Accepted
cancer (Breakthrough
Therapy &
Priority Review)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
acalabrutinib(#) BTK inhibitor B-cell malignancy Q1 2015 H1 2017
(Orphan drug)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
acalabrutinib(#) BTK inhibitor 1st-line CLL Q3 2015 2020 2020
(Orphan drug) (Orphan drug)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
acalabrutinib(#) BTK inhibitor r/r CLL, high risk Q4 2015 2020 2020
(Orphan drug) (Orphan drug)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
selumetinib MEK inhibitor differentiated thyroid cancer Q3 2013 2018 2018
ASTRA (Orphan drug)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
moxetumomab pasudotox(#) anti-CD22 recombinant hairy cell leukaemia Q2 2013 2018
PLAIT immunotoxin (Orphan drug)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) PACIFIC PD-L1 mAb stage III NSCLC Q2 2014 H2 2017 H2 2017 H2 2017
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb 3rd-line NSCLC Q2 2015 H2 2017 H2 2017 H2 2017
tremelimumab
ARCTIC
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb 1st-line NSCLC Q3 2015 H2 2017 H2 2017 H2 2017
tremelimumab
MYSTIC
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb 1st-line NSCLC Q4 2015 2019 2019 2019 2020
tremelimumab
NEPTUNE
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb 1st-line HNSCC Q4 2015 2018 2018 2018
tremelimumab
KESTREL
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb 2nd-line HNSCC Q4 2015 2018 2018 2018
tremelimumab
EAGLE
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb 1st-line bladder cancer Q4 2015 2018 2018 2018
tremelimumab
DANUBE
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Cardiovascular & Metabolic Diseases
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Brilinta(1) P2Y12 receptor arterial thrombosis Launched Launched Approved Launched
antagonist
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Farxiga(2) SGLT2 inhibitor type-2 diabetes Launched Launched Launched Accepted
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Epanova(#) omega-3 carboxylic acids severe hypertriglyceridemia Approved 2018
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
ZS-9 (sodium zirconium potassium binder hyperkalaemia Accepted Accepted
cyclosilicate)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
roxadustat(#) OLYMPUS hypoxia-inducible factor anaemia in CKD/ESRD Q3 2014 2018 Initiated(3)
(US) ROCKIES (US) prolyl hydroxylase
inhibitor
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Respiratory
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Bevespi Aerosphere LABA/LAMA COPD Launched(4) H1 2017 2018 2018
(PT003)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
benralizumab(#) IL-5R mAb severe asthma Accepted Accepted H1 2017 2020
CALIMA SIROCCO ZONDA
BISE
BORA
GREGALE
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
benralizumab(#) IL-5R mAb COPD Q3 2014 2018 2018 2019
TERRANOVA GALATHEA
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
PT010 LABA/LAMA/ICS COPD Q3 2015 2018 2018 2018 2019
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
tralokinumab IL-13 mAb severe asthma Q3 2014 2018 2018 2018
STRATOS 1,2
TROPOS
MESOS
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Other
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
anifrolumab(#) TULIP IFN-alphaR mAb systemic lupus erythematosus Q3 2015 2019 2019 2019
(Fast Track)
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
AZD3293(#) beta-secretase inhibitor Alzheimer's disease Q2 2016 2020 2020 2020
AMARANTH (Fast Track)
DAYBREAK-ALZ
------------------------- ------------------------- ------------------------------ ---------- ------------------ ------------------------- --------- -------------
Registrational Phase II trial
# Collaboration
1 Brilinta in the US and Japan; Brilique in ROW
2 Farxiga in the US; Forxiga in ROW
3 Rolling New Drug Application (NDA) regulatory submission initiated in Q4 2016
4 Bevespi Aerosphere (glycopyrrolate and formoterol fumarate)
inhalation aerosol was launched commercially in the US in January
2017
Phases I and II
NMEs and significant additional indications
Compound Mechanism Area Under Investigation Phase Date Commenced
Phase
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Oncology
--------------------------------------------------------------------------------------------------------------------------
durvalumab(#) PD-L1 mAb solid tumours II Q3 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb Hepatocellular carcinoma (liver cancer) II Q4 2016
tremelimumab
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb gastric cancer II Q2 2015
tremelimumab
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + CXCR2 HNSCC II Q3 2015
AZD5069
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + STAT3
AZD9150(#) inhibitor
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb+ BRAF inhibitor melanoma II Q1 2014
dabrafenib + + MEK inhibitor
trametinib
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + Wee1 solid tumours I Q4 2015
AZD1775(#) inhibitor
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + PD-1 mAb solid tumours I Q3 2016
MEDI0680
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab# or PD-L1 mAb or PD-L1 mAb + diffuse large B-cell lymphoma I Q3 2016
durvalumab# + (CTLA-4 mAb or STAT3
(tremelimumab or inhibitor)
AZD9150#)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb+ EGFR inhibitor NSCLC I Q2 2014
Iressa
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + humanised solid tumours I Q2 2016
MEDI0562(#) OX40 agonist
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + CD73 mAb solid tumours I Q1 2016
MEDI9447
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + NKG2a mAb solid tumours I Q1 2016
monalizumab
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + MEK inhibitor solid tumours I Q4 2015
selumetinib
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
durvalumab(#) + PD-L1 mAb + CTLA-4 mAb solid tumours I Q4 2013
tremelimumab
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
tremelimumab + CTLA-4 mAb + humanised solid tumours I Q2 2016
MEDI0562(#) OX40 agonist
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Lynparza + AZD6738 PARP inhibitor + ATR gastric cancer II Q3 2016
inhibitor
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Lynparza + PARP inhibitor + Wee1 solid tumours I Q3 2015
AZD1775(#) inhibitor
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
savolitinib(#) MET inhibitor papillary renal cell carcinoma II Q2 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Tagrisso + EGFR inhibitor + (MEK advanced EGFRm NSCLC II Q2 2016
(selumetinib(#) or inhibitor or MET
savolitinib(#) ) inhibitor)
TATTON
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Tagrisso BLOOM EGFR inhibitor CNS metastases in advanced EGFRm NSCLC II Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD1775(#) + Wee1 inhibitor + ovarian cancer II Q4 2012
chemotherapy chemotherapy
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD1775(#) Wee1 inhibitor solid tumours II Q1 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
vistusertib mTOR inhibitor solid tumours II Q1 2013
(AZD2014)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD5363(#) AKT inhibitor breast cancer II Q1 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD4547 FGFR inhibitor solid tumours II Q4 2011
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI-573(#) IGF mAb metastatic breast cancer II Q2 2012
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD0156 ATM inhibitor solid tumours I Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD2811(#) Aurora B inhibitor solid tumours I Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD4635 A2aR inhibitor solid tumours I Q2 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD6738 ATR inhibitor solid tumours I Q4 2013
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD8186 PI3k inhibitor solid tumours I Q2 2013
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD9150(#) STAT3 inhibitor haematological malignancies I Q1 2012
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD9496 selective oestrogen ER+ breast cancer I Q4 2014
receptor downregulator
(SERD)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI-565(#) CEA BiTE mAb solid tumours I Q1 2011
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI0562(#) humanised OX40 agonist solid tumours I Q1 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI0680 PD-1 mAb solid tumours I Q4 2013
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI1873 GITR agonist fusion solid tumours I Q4 2015
protein
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI4276 HER2 bispecific ADC mAb solid tumours I Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI9197(#) TLR 7/8 agonist solid tumours I Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI9447 CD73 mAb solid tumours I Q3 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Cardiovascular & Metabolic Diseases
--------------------------------------------------------------------------------------------------------------------------
MEDI0382 GLP-1/ diabetes / obesity II Q3 2016
glucagon dual agonist
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI4166 PCSK9/GLP-1 mAb + peptide diabetes / cardiovascular II Q1 2016
fusion
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI6012 LCAT ACS II Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD4076 anti-miR103/107 non-alcoholic fatty liver II Q4 2016
oligonucleotide disease/non-alcoholic steatohepatitis (NASH)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD4831 Myeloperoxidase Heart failure with a preserved ejection I Q3 2016
fraction
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD5718 FLAP CAD I Q1 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD8601(#) VEGF-A cardiovascular I Q1 2017
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI8111 Rh-factor II trauma / bleeding I Q1 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Respiratory
--------------------------------------------------------------------------------------------------------------------------
tezepelumab(#) TSLP mAb asthma / atopic dermatitis II Q2 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
abediterol(#) LABA asthma/COPD II Q4 2007
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD7594 inhaled SGRM asthma/COPD II Q3 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD9412(#) inhaled interferon beta asthma/COPD II Q3 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
PT010 LABA/LAMA/ICS asthma II Q2 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD1419(#) TLR9 agonist asthma II Q4 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD8871(#) MABA COPD II Q1 2017
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD0284 Inhaled RORg psoriasis I Q4 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD5634 inhaled ENaC cystic fibrosis I Q1 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD7594+abediterol# Inhaled SGRM+LABA asthma/COPD I Q4 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD7986(#) DPP1 COPD I Q4 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD9567 oral SGRM rheumatoid arthritis I Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
Other
--------------------------------------------------------------------------------------------------------------------------
anifrolumab(#) IFN-alphaR mAb lupus nephritis II Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
anifrolumab(#) IFN-alphaR mAb systemic lupus erythematosus (subcutaneous) I Q4 2015
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
inebilizumab(#) CD19 mAb neuromyelitis optica II Q1 2015
(Orphan drug)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
mavrilimumab(#) GM-CSFR mAb rheumatoid arthritis II Q1 2010
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
verinurad(1) selective uric acid chronic treatment of hyperuricemia in patients II Q3 2013
reabsorption inhibitor with gout
(URAT-1)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI5872(#) B7RP1 mAb primary Sjögren's syndrome II Q3 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
AZD3241 myeloperoxidase inhibitor multiple system atrophy II Q2 2015
(Orphan drug)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI3902 Psl/PcrV bispecific mAb prevention of nosocomial pseudomonas pneumonia II Q2 2016
(Fast Track,
US)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI4893 mAb binding to S. aureus hospital-acquired pneumonia / serious S. aureu II Q4 2014
toxin s infection
(Fast Track,
US)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI8852 influenza A mAb influenza A treatment II Q4 2015
(Fast Track,
US)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI8897(#) RSV mAb-YTE passive RSV prophylaxis II Q1 2015
(Fast Track,
US)
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI0700(#) BAFF/B7RP1 bispecific mAb systemic lupus erythematosus I Q1 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI1814(#2) amyloid beta mAb Alzheimer's disease I Q2 2014
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI4920 anti-CD40L-Tn3 fusion primary Sjögren's syndrome I Q2 2014
protein
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI7352 NGF/TNF bispecific mAb osteoarthritis pain I Q1 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI7734 ILT7 mAb myositis I Q3 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
MEDI9314 IL-4R mAb atopic dermatitis I Q1 2016
-------------------- -------------------------- ----------------------------------------------- ------ ---------------
# Collaboration
1 Planning to initiate a programme for CKD
2 Co-development collaboration with Eli Lilly for MEDI1814
Significant Lifecycle Management
Compound Mechanism Area Under Investigation Date Estimated Regulatory Acceptance Date / Submission
Commenced Status
Phase
----------------- --------------- ---------------------------------------------- ---------- -----------------------------------------------------
US EU Japan China
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Oncology
-----------------------------------------------------------------------------------------------------------------------------------------------------
Faslodex oestrogen 1st-line hormone receptor +ve advanced breast Accepted Accepted Accepted H2 2017
FALCON receptor cancer
antagonist
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor gBRCA metastatic breast cancer Q2 2014 H2 2017 H2 2017 H2 2017
OlympiAD
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor 2nd-line or greater BRCAm PSR ovarian cancer, Q3 2013 H1 2017 H1 2017 H2 2017
maintenance monotherapy
SOLO-2 (Fast Track)
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor 1st-line BRCAm ovarian cancer Q3 2013 2018 2018 2018
SOLO-1
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor gBRCA PSR ovarian cancer Q1 2015 2018
SOLO-3
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor pancreatic cancer Q1 2015 2018 2018
POLO
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor prostate cancer Q3 2014 (Breakthrough
Therapy)
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Lynparza PARP inhibitor gBRCA adjuvant breast cancer Q2 2014 2020 2020 2020
OlympiA
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Tagrisso EGFR inhibitor 1st-line advanced EGFRm NSCLC Q1 2015 H2 2017 H2 2017 H2 2017 H2 2017
FLAURA
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Tagrisso EGFR inhibitor adjuvant EGFRm NSCLC Q4 2015 2022 2022 2022 2022
ADAURA
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Cardiovascular & Metabolic Diseases
-----------------------------------------------------------------------------------------------------------------------------------------------------
Brilinta(1) P2Y12 receptor outcomes trial in patients with prior Launched Launched Approved Accepted
PEGASUS- antagonist myocardial infarction (Priority Review)
TIMI 54
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Brilinta(1) P2Y12 receptor outcomes trial in patients with type-2 Q1 2014 2018 2018 2018 2019
THEMIS antagonist diabetes and CAD, but without a previous
history of
myocardial infarction or stroke
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Brilinta(1) P2Y12 receptor prevention of vaso-occlusive crises in Q1 2014 2020 2020
HESTIA antagonist paediatric patients with sickle cell disease
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Onglyza DPP-4 type-2 diabetes outcomes trial Launched Launched Accepted
SAVOR-TIMI 53 inhibitor
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Kombiglyze DPP-4 type-2 diabetes Launched Launched Accepted
XR/Komboglyze(2) inhibitor/
metformin FDC
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Farxiga(3) SGLT2 type-2 diabetes outcomes trial Q2 2013 2020 2020
DECLARE- inhibitor
TIMI 58
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Farxiga(3) SGLT2 type-1 diabetes Q4 2014 2018 2018 2018
inhibitor
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Xigduo XR/ SGLT2 type-2 diabetes Launched Launched
Xigduo(4) inhibitor/
metformin FDC
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Qtern DPP-4 type-2 diabetes Accepted Approved
(saxagliptin/ inhibitor/
dapagliflozin SGLT2
FDC) inhibitor FDC
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Bydureon weekly GLP-1 receptor type-2 diabetes Q1 2013 H1 2017 H2 2017
suspension agonist
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Bydureon EXSCEL GLP-1 receptor type-2 diabetes outcomes trial Q2 2010 2018 2018 2018
agonist
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Epanova omega-3 outcomes trial in statin-treated patients at Q4 2014 2020 2020 2020 2020
STRENGTH carboxylic high CV risk, with persistent
acids hypertriglyceridemia
plus low HDL-cholesterol
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Respiratory
-----------------------------------------------------------------------------------------------------------------------------------------------------
Symbicort ICS/LABA as-needed use in mild asthma Q4 2014 2018 2019
SYGMA
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Symbicort ICS/LABA breath actuated Inhaler asthma/COPD 2018
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Duaklir LAMA/LABA COPD 2018 Launched 2019
Genuair(#)
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Other
-----------------------------------------------------------------------------------------------------------------------------------------------------
Nexium proton pump stress ulcer prophylaxis Submitted
inhibitor
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
Nexium proton pump paediatrics Launched Launched Accepted
inhibitor
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
linaclotide# GC-C receptor irritable bowel syndrome with constipation Accepted
peptide (IBS-C)
agonist
----------------- --------------- ---------------------------------------------- ---------- ------------------ --------- --------- -----------
# Collaboration
1 Brilinta in the US and Japan; Brilique in ROW
2 Kombiglyze XR in the US; Komboglyze in the EU
3 Farxiga in the US; Forxiga in ROW
4 Xigduo XR in the US; Xigduo in the EU
Terminations (discontinued projects between 1 October 2016 and
31 December 2016)
NME / Line Extension Compound Reason for Area Under Investigation
Discontinuation
--------------------- --------------------------- ----------------- -------------------------
NME durvalumab# + tremelimumab Safety/Efficacy metastatic pancreatic
ALPS ductal carcinoma
--------------------- --------------------------- ----------------- -------------------------
NME MEDI7510 Safety/Efficacy Prevention of
respiratory
syncytial virus
disease in older
patients
--------------------- --------------------------- ----------------- -------------------------
Completed Projects / Divestitures
Compound Mechanism Area Under Investigation Completed/ Estimated Regulatory Submission
Divested Acceptance
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- -----------------------------------
US EU Japan China
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
MEDI2070(#1) IL-23 mAb Crohn's disease Divested
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
Zinforo(#2) extended spectrum cephalosporin with pneumonia/skin infections Divested Launched Submitted
affinity to penicillin-binding proteins
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
Zavicefta(#2) cephalosporin/ beta lactamase inhibitor hospital-acquired pneumonia/ ventilator-associated pneumonia Divested Approved
(CAZ AVI)
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
Zavicefta(#2) cephalosporin/ beta lactamase inhibitor serious infections, complicated intra-abdominal infection, c Divested Approved
omplicated urinary tract infection
(CAZ AVI)
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
ATM AVI(#2) monobactam/ beta lactamase inhibitor targeted serious bacterial infections Divested
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
CXL(#2) beta lactamase inhibitor / methicillin-resistant S. aureus Divested
cephalosporin
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
AZD8108 NMDA antagonist suicidal ideation Divested
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
durvalumab(#) PD-L1 mAb 2nd-line HNSCC (PD-L1 positive) Completed
HAWK (3)
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
durvalumab(#) PD-L1 mAb + CTLA-4 mAb 2nd-line HNSCC (PD-L1 negative) Completed
+
tremelimumab
CONDOR (3)
-------------- ---------------------------------------- ------------------------------------------------------------- ----------- --- --------- ------ -----------
1 AstraZeneca licensing agreement with Allergan
2 AstraZeneca completed the transaction with Pfizer to sell the
commercialisation and development rights to its late-stage,
small-molecule antibiotics business in most markets globally
outside the US
3 Registrational trials now complete (data will contribute
towards subsequent HNSCC regulatory submissions)
Condensed Consolidated Statement of Comprehensive Income
For the year ended 31 December 2016 2015
$m $m
-------------------------------------------- -------- ---------
Product sales 21,319 23,641
Externalisation revenue 1,683 1,067
------------------------------------------------- -------- ---------
Total revenue 23,002 24,708
Cost of sales (4,126) (4,646)
------------------------------------------------- -------- ---------
Gross profit 18,876 20,062
Distribution costs (326) (339)
Research and development expense (5,890) (5,997)
Selling, general and administrative
costs (9,413) (11,112)
Other operating income and expense 1,655 1,500
---------
Operating profit 4,902 4,114
Finance income 67 46
Finance expense (1,384) (1,075)
Share of after tax losses in associates
and joint ventures (33) (16)
------------------------------------------------- -------- ---------
Profit before tax 3,552 3,069
Taxation (146) (243)
------------------------------------------------- -------- ---------
Profit for the period 3,406 2,826
------------------------------------------------- -------- ---------
Other comprehensive income
Items that will not be reclassified
to profit or loss
Remeasurement of the defined benefit
pension liability (575) 652
Tax on items that will not be reclassified
to profit or loss 136 (199)
------------------------------------------------- -------- ---------
(439) 453
-------- ---------
Items that may be reclassified
subsequently to profit or loss
Foreign exchange arising on consolidation (1,050) (528)
Foreign exchange arising on designating
borrowings in net investment hedges (591) (333)
Fair value movements on cash flow (115) -
hedges
Fair value movements on cash flow 195 -
hedges transferred to profit or
loss
Fair value movements on derivatives
designated in net investment hedges (4) 14
Amortisation of loss on cash flow
hedge 1 1
Net available for sale gains/(losses)
taken to equity 139 (32)
Tax on items that may be reclassified
subsequently to profit or loss 86 87
------------------------------------------------- -------- ---------
(1,339) (791)
-------- ---------
Other comprehensive income for
the period, net of tax (1,778) (338)
------------------------------------------------- -------- ---------
Total comprehensive income for
the period 1,628 2,488
------------------------------------------------- -------- ---------
Profit attributable to:
Owners of the Parent 3,499 2,825
Non-controlling interests (93) 1
------------------------------------------------- -------- ---------
3,406 2,826
Total comprehensive income attributable
to:
Owners of the Parent 1,722 2,488
Non-controlling interests (94) -
-------------------------------------------- -------- ---------
1,628 2,488
-------- ---------
Basic earnings per $0.25 Ordinary
Share $2.77 $2.23
Diluted earnings per $0.25 Ordinary
Share $2.76 $2.23
------------------------------------------------- -------- ---------
Weighted average number of Ordinary
Shares in issue (millions) 1,265 1,264
Diluted weighted average number
of Ordinary Shares in issue (millions) 1,266 1,265
------------------------------------------------- -------- ---------
Condensed Consolidated Statement of Comprehensive Income
For the quarter ended 31 December 2016 2015
$m $m
--------------------------------------------- -------- --------
Product sales 5,260 6,207
Externalisation revenue 325 192
-------------------------------------------------- -------- --------
Total revenue 5,585 6,399
Cost of sales (1,160) (1,269)
-------------------------------------------------- -------- --------
Gross profit 4,425 5,130
Distribution costs (83) (99)
Research and development expense (1,543) (1,746)
Selling, general and administrative
costs (1,386) (2,668)
Other operating income and expense 1,120 471
--------
Operating profit 2,533 1,088
Finance income 23 13
Finance expense (362) (292)
Share of after tax losses in associates
and joint ventures (11) (7)
-------------------------------------------------- -------- --------
Profit before tax 2,183 802
Taxation (366) 6
-------------------------------------------------- -------- --------
Profit for the period 1,817 808
-------------------------------------------------- -------- --------
Other comprehensive income
Items that will not be reclassified
to profit or loss
Remeasurement of the defined benefit
pension liability 552 618
Tax on items that will not be reclassified
to profit or loss (120) (187)
-------------------------------------------------- -------- --------
432 431
-------- --------
Items that may be reclassified subsequently
to profit or loss
Foreign exchange arising on consolidation (360) (169)
Foreign exchange arising on designating
borrowings in net investment hedges (397) (11)
Fair value movements on cash flow (89) -
hedges
Fair value movements on cash flow 154 -
hedges transferred to profit or
loss
Fair value movements on derivatives
designated in net investment hedges 92 (10)
Net available for sale gains taken
to equity 13 31
Tax on items that may be reclassified
subsequently to profit or loss 23 3
-------------------------------------------------- -------- --------
(564) (156)
-------- --------
Other comprehensive income for the
period, net of tax (132) 275
-------------------------------------------------- -------- --------
Total comprehensive income for the
period 1,685 1,083
-------------------------------------------------- -------- --------
Profit attributable to:
Owners of the Parent 1,842 808
Non-controlling interests (25) -
--------------------------------------------- -------- --------
1,817 808
Total comprehensive income attributable
to:
Owners of the Parent 1,710 1,083
Non-controlling interests (25) -
--------------------------------------------- -------- --------
1,685 1,083
-------- --------
Basic earnings per $0.25 Ordinary
Share $1.46 $0.63
Diluted earnings per $0.25 Ordinary
Share $1.45 $0.63
-------------------------------------------------- -------- --------
Weighted average number of Ordinary
Shares in issue (millions) 1,265 1,264
Diluted weighted average number
of Ordinary Shares in issue (millions) 1,266 1,265
-------------------------------------------------- -------- --------
Condensed Consolidated Statement of Financial Position
Restated*
At 31 Dec 2016 At 31 Dec 2015
$m $m
---------------------------------------------------------------- ----------------- -----------------
ASSETS Non-current assets
Property, plant and equipment 6,848 6,413
Goodwill 11,658 11,800
Intangible assets 27,586 22,646
Derivative financial instruments 343 446
Investments in associates and joint ventures 99 85
Other investments 727 458
Other receivables 901 907
Deferred tax assets 1,102 1,294
---------------------------------------------------------------------- ----------------- -----------------
49,264 44,049
----------------- -----------------
Current assets
Inventories 2,334 2,143
Trade and other receivables 4,573 6,622
Other investments 884 613
Derivative financial instruments 27 2
Income tax receivable 426 387
Cash and cash equivalents 5,018 6,240
---------------------------------------------------------------------- ----------------- -----------------
13,262 16,007
----------------- -----------------
Total assets 62,526 60,056
---------------------------------------------------------------------- ----------------- -----------------
LIABILITIES Current liabilities
Interest-bearing loans and borrowings (2,307) (916)
Trade and other payables (10,486) (11,663)
Derivative financial instruments (18) (9)
Provisions (1,065) (798)
Income tax payable (1,380) (1,483)
---------------------------------------------------------------------- ----------------- -----------------
(15,256) (14,869)
----------------- -----------------
Non-current liabilities
Interest-bearing loans and borrowings (14,501) (14,137)
Derivative financial instruments (117) (1)
Deferred tax liabilities (3,956) (2,665)
Retirement benefit obligations (2,186) (1,974)
Provisions (353) (444)
Other payables (9,488) (7,457)
---------------------------------------------------------------------- ----------------- -----------------
(30,601) (26,678)
----------------- -----------------
Total liabilities (45,857) (41,547)
---------------------------------------------------------------------- ----------------- -----------------
Net assets 16,669 18,509
---------------------------------------------------------------------- ----------------- -----------------
EQUITY
Capital and reserves attributable to equity holders of the
Company
Share capital 316 316
Share premium account 4,351 4,304
Other reserves 2,047 2,036
Retained earnings 8,140 11,834
---------------------------------------------------------------------- ----------------- -----------------
14,854 18,490
Non-controlling interests 1,815 19
---------------------------------------------------------------------- ----------------- -----------------
Total equity 16,669 18,509
---------------------------------------------------------------------- ----------------- -----------------
*2015 comparatives have been restated to reflect an adjustment
to the acquisition accounting for ZS Pharma (see Note 5).
Condensed Consolidated Statement of Cash Flows
For the year ended 31 December 2016 2015
$m $m
-------------------------------------------------------------------------------------- --------- --------
Cash flows from operating activities
Profit before tax 3,552 3,069
Finance income and expense 1,317 1,029
Share of after tax losses in associates and joint ventures 33 16
Depreciation, amortisation and impairment 2,357 2,852
Decrease/(increase) in working capital and short-term provisions 926 (49)
Gain on disposal of intangible assets (1,301) (961)
Fair value movements on contingent consideration arising from business combinations (1,158) (432)
Non-cash and other movements (492) (350)
-------------------------------------------------------------------------------------------- --------- --------
Cash generated from operations 5,234 5,174
Interest paid (677) (496)
Tax paid (412) (1,354)
-------------------------------------------------------------------------------------------- --------- --------
Net cash inflow from operating activities 4,145 3,324
-------------------------------------------------------------------------------------------- --------- --------
Cash flows from investing activities
Movement in short-term investments and fixed deposits (166) 283
Purchase of property, plant and equipment (1,446) (1,328)
Disposal of property, plant and equipment 82 47
Purchase of intangible assets (868) (1,460)
Disposal of intangible assets 1,427 1,130
Purchase of non-current asset investments (230) (57)
Disposal of non-current asset investments 3 93
Payments to joint ventures (41) (45)
Upfront payments on business combinations (2,564) (2,446)
Payment of contingent consideration from business combinations (293) (579)
Interest received 140 123
Payments made by subsidiaries to non-controlling interests (13) -
Net cash outflow from investing activities (3,969) (4,239)
-------------------------------------------------------------------------------------------- --------- --------
Net cash inflow/(outflow) before financing activities 176 (915)
-------------------------------------------------------------------------------------------- --------- --------
Cash flows from financing activities
Proceeds from issue of share capital 47 43
New long-term loans 2,491 5,928
Repayment of loans - (884)
Dividends paid (3,561) (3,486)
Hedge contracts relating to dividend payments 18 (51)
Repayment of obligations under finance leases (16) (42)
Movement in short-term borrowings (303) (630)
Net cash (outflow)/inflow from financing activities (1,324) 878
-------------------------------------------------------------------------------------------- --------- --------
Net decrease in cash and cash equivalents in the period (1,148) (37)
Cash and cash equivalents at the beginning of the period 6,051 6,164
Exchange rate effects 21 (76)
-------------------------------------------------------------------------------------------- --------- --------
Cash and cash equivalents at the end of the period 4,924 6,051
-------------------------------------------------------------------------------------------- --------- --------
Cash and cash equivalents consists of:
Cash and cash equivalents 5,018 6,240
Overdrafts (94) (189)
-------------------------------------------------------------------------------------------- --------- --------
4,924 6,051
--------- --------
Condensed Consolidated Statement of Changes in Equity
Share Non-
Share premium Other Retained controlling Total
capital account reserves* earnings Total interests equity
$m $m $m $m $m $m $m
--------------------------
At 1 Jan 2015 316 4,261 2,021 13,029 19,627 19 19,646
Profit for the period - - - 2,825 2,825 1 2,826
Other comprehensive income - - - (337) (337) (1) (338)
Transfer to other reserves - - 15 (15) - - -
Transactions with owners:
Dividends - - - (3,537) (3,537) - (3,537)
Issue of Ordinary Shares - 43 - - 43 - 43
Share-based payments - - - (131) (131) - (131)
Net movement - 43 15 (1,195) (1,137) - (1,137)
At 31 Dec 2015 316 4,304 2,036 11,834 18,490 19 18,509
Share Non-
Share premium Other Retained controlling Total
capital account reserves* earnings Total interests equity
$m $m $m $m $m $m $m
At 1 Jan 2016 316 4,304 2,036 11,834 18,490 19 18,509
Profit for the period - - - 3,499 3,499 (93) 3,406
Other comprehensive income - - - (1,777) (1,777) (1) (1,778)
Transfer to other reserves - - 11 (11) - - -
Transactions with owners:
Dividends - - - (3,540) (3,540) - (3,540)
Dividend paid by
subsidiary to
non-controlling interest - - - - - (13) (13)
Acerta put option - - - (1,825) (1,825) - (1,825)
Changes in non-controlling
interest - - - - - 1,903 1,903
Issue of Ordinary Shares - 47 - - 47 - 47
Share-based payments - - - (40) (40) - (40)
Net movement - 47 11 (3,694) (3,636) 1,796 (1,840)
At 31 Dec 2016 316 4,351 2,047 8,140 14,854 1,815 16,669
* Other reserves include the capital redemption reserve and the merger reserve.
Notes to the Interim Financial Statements
1 BASIS OF PREPARATION AND ACCOUNTING POLICIES
The preliminary announcement for the year ended 31 December 2016
has been prepared in accordance with International Financial
Reporting Standards (IFRSs) as adopted by the European Union (EU)
and as issued by the International Accounting Standards Board
(IASB).
The annual financial statements of the Group are prepared in
accordance with IFRSs as adopted by the EU and as issued by the
IASB. The preliminary announcement has been prepared applying the
accounting policies and presentation that were applied in the
preparation of the Group's published consolidated financial
statements for the year ended 31 December 2015. There have been no
significant new or revised accounting standards applied in the 12
months ended 31 December 2016.
Legal proceedings
The information contained in Note 7 updates the disclosures
concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form 20-F Information 2015 and Interim
Financial Statements for the six months ended 30 June 2016 and the
Third Quarter and Nine Months Results 2016.
Going concern
The Group has considerable financial resources available. As at
31 December 2016 the Group has $5.7bn in financial resources (cash
balances of $5bn and undrawn committed bank facilities of $3bn
which are available until April 2021, with only $2.3bn of debt due
within one year). The Group's revenues are largely derived from
sales of products which are covered by patents which provide a
relatively high level of resilience and predictability to cash
inflows, although our revenue is expected to continue to be
significantly impacted by the expiry of patents over the medium
term. In addition, government price interventions in response to
budgetary constraints are expected to continue to adversely affect
revenues in many of our mature markets. However, we anticipate new
revenue streams from both recently launched medicines and products
in development, and the Group has a wide diversity of customers and
suppliers across different geographic areas. Consequently, the
Directors believe that, overall, the Group is well placed to manage
its business risks successfully.
On the basis of the above paragraph and after making enquiries,
the Directors have a reasonable expectation that the Company and
the Group have adequate resources to continue in operational
existence for the foreseeable future. Accordingly, the preliminary
announcement has been prepared on a going concern basis.
Financial information
The financial information contained in the preliminary
announcement does not constitute statutory accounts of the Group
for the years ended 31 December 2016 and 2015 but is derived from
those accounts. Statutory accounts for 2015 have been delivered to
the registrar of companies and those for 2016 will be delivered in
due course. Those accounts have been reported on by the Group's
auditors; their report was (i) unqualified, (ii) did not include a
reference to any matters to which the auditors drew attention by
way of emphasis without qualifying their report, and (iii) did not
contain a statement under section 498(2) or (3) of the Companies
Act 2006. The quarterly information for the three month period to
31 December 2016 and to 31 December 2015 has not been subject to
audit.
2 RESTRUCTURING COSTS
Profit before tax for the year ended 31 December 2016 is stated
after charging restructuring costs of $1,107m ($394m for the fourth
quarter of 2016). These have been charged to profit as follows:
FY 2016 FY 2015 Q4 2016 Q4 2015
$m $m $m $m
Cost of sales 130 158 43 34
Research and development expense 178 258 32 78
Selling, general and administrative costs 823 618 319 260
Other operating income and expense (24) - - -
Total 1,107 1,034 394 372
3 NET DEBT
The table below provides an analysis of net debt and a
reconciliation of net cash flow to the movement in net debt.
At 1 Jan Cash Flow Acquisitions Non-cash Exchange Movements At 31 Dec
2016 $m & Other $m 2016
$m $m $m $m
Loans due after one year (14,109) (2,491) - 1,793 312 (14,495)
Finance leases due after
one year (28) - - 22 - (6)
Total long-term debt (14,137) (2,491) - 1,815 312 (14,501)
Current instalments of
loans - - - (1,769) - (1,769)
Current instalments of
finance leases (67) 16 - (37) 1 (87)
Total current debt (67) 16 - (1,806) 1 (1,856)
Other Investments 613 164 140 54 (73) 898
Net derivative financial
instruments 438 (2) - (201) - 235
Cash and cash equivalents 6,240 (1,231) - - 9 5,018
Overdrafts (189) 83 - - 12 (94)
Short-term borrowings (660) 303 - 1 (1) (357)
6,442 (683) 140 (146) (53) 5,700
Net debt (7,762) (3,158) 140 (137) 260 (10,657)
Non-cash movements in the period include fair value adjustments
under IAS 39.
4 MAJORITY EQUITY INVESTMENT IN ACERTA PHARMA
On 2 February 2016, AstraZeneca completed an agreement to invest
in a majority equity stake in Acerta Pharma, a privately-owned
biopharmaceutical company based in the Netherlands and US. The
transaction provides AstraZeneca with a potential best-in-class
irreversible oral Bruton's tyrosine kinase (BTK) inhibitor,
acalabrutinib (ACP-196), currently in Phase III development for
B-cell blood cancers and in Phase I/II clinical trials in multiple
solid tumours.
Under the terms of the agreement, AstraZeneca has acquired 55%
of the issued share capital of Acerta for an upfront payment of
$2.5bn. A further payment of $1.5bn will be paid either on receipt
of the first regulatory approval for acalabrutinib for any
indication in the US, or the end of 2018, depending on which is
first. The agreement also includes options which, if exercised,
provide the opportunity for Acerta shareholders to sell, and
AstraZeneca to buy, the remaining 45% of shares in Acerta. The
options can be exercised at various points in time, conditional on
the first approval of acalabrutinib in both the US and Europe and
when the extent of the commercial opportunity has been fully
established, at a price of approximately $3bn net of certain costs
and payments incurred by AstraZeneca and net of agreed future
adjusting items, using a pre-agreed pricing mechanism. Acerta has
approximately 150 employees.
AstraZeneca's 55% holding is a controlling interest and Acerta's
combination of intangible product rights with an established
workforce and their operating processes requires that the
transaction is accounted for as a business combination in
accordance with IFRS 3.
Goodwill is principally attributable to the value of the
specialist knowhow inherent in the acquired workforce and the
accounting for deferred taxes. Goodwill is not expected to be
deductible for tax purposes. Acerta Pharma's results have been
consolidated into the Group's results from 2 February 2016. From
the period from acquisition to 31 December 2016, Acerta Pharma had
no revenues and its loss after tax was $212m.
In the period since 2 February 2016, the acquisition accounting
has been adjusted to reflect new information regarding the value of
net assets acquired with Acerta. This has resulted in an increase
in other assets of $15m, a decrease in deferred tax liabilities of
$50m, and a decrease in goodwill of $65m.
Fair value
$m
Intangible assets 7,307
Other assets including cash and cash equivalents 253
Deferred tax liabilities (1,777)
Other liabilities (90)
Total net assets acquired 5,693
Non-controlling interests (1,903)
Goodwill 19
Fair value of total consideration 3,809
Less: fair value of deferred consideration (1,332)
Total upfront consideration 2,477
Less: cash and cash equivalents acquired (94)
Net cash outflow 2,383
5 ACQUISITION OF ZS PHARMA
On 17 December 2015, AstraZeneca completed the acquisition of ZS
Pharma, a biopharmaceutical company based in San Mateo, California.
ZS Pharma uses its proprietary ion-trap technology to develop novel
treatments for hyperkalaemia, a serious condition of elevated
potassium in the bloodstream, typically associated with CKD and
Chronic Heart Failure.
During 2016, we revised our assessment of the fair values of the
assets and liabilities acquired as a result of new information
obtained about facts and circumstances that existed at the date of
acquisition that impact the value of deferred tax. This has
resulted in a reduction to both deferred tax liabilities and
goodwill of $68m.
Fair value
$m
Non-current assets
Intangible assets 3,162
Property, plant and equipment 21
3,183
Current assets 169
Current liabilities (50)
Non-current liabilities
Deferred tax liabilities (977)
Other liabilities (13)
(990)
Total net assets acquired 2,312
Goodwill 388
Total upfront consideration 2,700
Less: cash and cash equivalents acquired (73)
Less: deferred upfront consideration (181)
Net cash outflow 2,446
6 FINANCIAL INSTRUMENTS
As detailed in the Group's most recent annual financial
statements, our principal financial instruments consist of
derivative financial instruments, other investments, trade and
other receivables, cash and cash equivalents, trade and other
payables, and interest-bearing loans and borrowings. As indicated
in Note 1, there have been no changes to the accounting policies
for financial instruments, including fair value measurement, from
those disclosed on pages 146 and 147 of the Company's Annual Report
and Form 20-F Information 2015. In addition, there have been no
changes of significance to the categorisation or fair value
hierarchy of our financial instruments. Financial instruments
measured at fair value include $1,611m of other investments,
$1,719m of loans, and $235m of derivatives as at 31 December 2016.
The total fair value of interest-bearing loans and borrowings at 31
December 2016 which have a carrying value of $16,808m in the
Condensed Consolidated Statement of Financial Position, was
$18,174m. Contingent consideration liabilities arising on business
combinations have been classified under Level 3 in the fair value
hierarchy and movements in fair value are shown below:
Diabetes Other Total Total
Alliance
2016 2016 2016 2015
$m $m $m $m
At 1 January 5,092 1,319 6,411 6,899
Settlements (242) (51) (293) (579)
Revaluations (999) (159) (1,158) (432)
Discount unwind 389 108 497 524
Foreign exchange - - - (1)
At 31 December 4,240 1,217 5,457 6,411
7 LEGAL PROCEEDINGS AND CONTINGENT LIABILITIES
AstraZeneca is involved in various legal proceedings considered
typical to its business, including litigation and investigations
relating to product liability, commercial disputes, infringement of
intellectual property rights, the validity of certain patents,
anti-trust law and sales and marketing practices. The matters
discussed below constitute the more significant developments since
publication of the disclosures concerning legal proceedings in the
Company's Annual Report and Form 20-F Information 2015 and as part
of the Company's Half-Yearly Financial Report for the six-month
period to 30 June 2016 and the Third Quarter and Nine-Month Results
2016 (the Disclosures). Unless noted otherwise below or in the
Disclosures, no provisions have been established in respect of the
claims discussed below.
As discussed in the Disclosures, for the majority of claims in
which AstraZeneca is involved it is not possible to make a
reasonable estimate of the expected financial effect, if any, that
will result from ultimate resolution of the proceedings. In these
cases, AstraZeneca discloses information with respect only to the
nature and facts of the cases but no provision is made.
In cases that have been settled or adjudicated, or where
quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able
to make a reasonable estimate of the loss, we record the loss
absorbed or make a provision for our best estimate of the expected
loss.
The position could change over time and the estimates that we
have made and upon which we have relied in calculating these
provisions are inherently imprecise. There can, therefore, be no
assurance that any losses that result from the outcome of any legal
proceedings will not exceed the amount of the provisions that have
been booked in the accounts. The major factors causing this
uncertainty are described more fully in the Disclosures and
herein.
AstraZeneca has full confidence in, and will vigorously defend
and enforce, its intellectual property.
Matters disclosed in respect of the fourth quarter of 2016 and
to 2 February 2017.
Patent litigation
Faslodex (fulvestrant)
US patent proceedings
As previously disclosed, AstraZeneca has filed patent
infringement lawsuits in the US District Court in New Jersey (the
District Court) relating to four patents listed in the FDA Orange
Book with reference to Faslodex after AstraZeneca received
Paragraph IV notices relating to six Abbreviated New Drug
Applications (ANDAs) seeking FDA approval to market generic
versions of Faslodex prior to the expiration of AstraZeneca's
patents. In December 2016, AstraZeneca settled the lawsuit against
one of the ANDA filers, and the District Court entered a consent
judgment in January 2017 which ended that particular lawsuit.
AstraZeneca continues to litigate in the District Court against two
other ANDA filers.
As previously disclosed, in July 2016, AstraZeneca was served
with four petitions for inter partes review by the Patent Trial and
Appeal Board (PTAB) relating to each of the four Orange Book-listed
patents. In December 2016, the PTAB issued an order denying
institution of the first of the four petitions. In January 2017,
the PTAB terminated the remaining petitions at the request of the
parties.
Patent proceedings outside the US
As previously disclosed, in Germany, in July 2015, AstraZeneca
was served with complaints filed by Hexal AG (Hexal) and ratiopharm
GmbH (ratiopharm) requesting the revocation of the German part of
European Patent No. EP 1250138 (the '138 Patent). Following an oral
hearing in January 2017, the German Federal Patent Court declared
the patent invalid. AstraZeneca intends to appeal. In January 2017,
the Regional Court of Düsseldorf suspended the effects of a
provisional injunction based on the '138 patent which had been in
place against Hexal since February 2016. Hexal is also seeking to
lift a provisional injunction based on European Patent No. EP
2266573. In January 2017, the Higher Regional Court of Düsseldorf
lifted a provisional injunction based on the '138 patent which had
been in place against ratiopharm since September 2016.
As previously disclosed, in China, in March 2014, AstraZeneca
received a request for invalidation of the Faslodex formulation
patent, CN01803546.9, filed by Jiangsu Hansoh Pharmaceutical Co.
Ltd. at the Chinese Patent Office. In September 2014, the Patent
Re-examination Board of the Chinese Patent Board declared the
patent invalid. AstraZeneca appealed to the Beijing IP Court and
the appeal was rejected in April 2016. AstraZeneca appealed this
decision to the Beijing Higher People's Court and the appeal was
rejected in December 2016. AstraZeneca is considering its
options.
Onglyza (saxagliptin) and Kombiglyze (saxagliptin and
metformin)
US patent proceedings
As previously disclosed, in June 2016, the US Court of Appeals
for the Federal Circuit denied Mylan Pharmaceuticals Inc.'s (Mylan)
petition for rehearing en banc of the decision affirming the denial
of Mylan's motion to dismiss for lack of jurisdiction. In September
2016, Mylan filed a petition for writ of certiorari with the
Supreme Court of the United States seeking an appeal of that
decision and, in January 2017, the writ was denied.
As previously disclosed, in May 2016, the US Patent and
Trademark Office (USPTO) instituted an inter partes review brought
by Mylan Pharmaceuticals Inc. challenging the validity of US Patent
No. RE44,186 (the '186 Patent) (the Mylan IPR). Subsequently,
Wockhardt Bio AG, Teva Pharmaceuticals USA Inc., Sun Pharmaceutical
Industries Ltd., Sun Pharma Global FZE, and Amneal Pharmaceuticals
LLC also filed petitions for inter partes review challenging the
validity of the '186 Patent and joined the Mylan IPR. A hearing in
the Mylan IPR was held in January 2017. A decision is awaited.
Crestor (rosuvastatin)
US patent proceedings
As previously disclosed, in December 2015, the US District Court
for the District of South Carolina (the District Court) dismissed
and entered judgment in AstraZeneca's favour in a patent
infringement lawsuit filed by plaintiff Palmetto Pharmaceuticals,
LLC (Palmetto), which, among other things, claimed that
AstraZeneca's Crestor sales induced infringement of Palmetto's
patent. Palmetto subsequently appealed. In December 2016, the
Federal Circuit Court of Appeals affirmed the District Court's
order dismissing the lawsuit.
Patent proceedings outside the US
As previously disclosed, in Japan, in March 2015, an individual
filed a patent invalidation request with the Japanese Patent Office
(JPO) in relation to the Crestor substance patent. In July 2016,
the JPO dismissed the request. The individual has appealed to the
Intellectual Property High Court of Japan (the High Court) with the
intervention of Nippon Chemiphar Co. Ltd (Nippon). In addition,
Nippon commenced a separate patent invalidation request with the
JPO in relation to the Crestor substance patent. In November 2016,
the JPO denied the request. Nippon has appealed to the High
Court.
Synagis (palivizumab)
US patent proceedings
In December 2016, UCB BioPharma SPRL (UCB) filed a complaint
against MedImmune LLC in the US District Court for the District of
Delaware alleging infringement of US Patent No. 7,566,771. The
complaint relates to a royalty-bearing license between Celltech
R&D LTD and MedImmune which was terminated by MedImmune in
2010.
Losec/Prilosec (omeprazole)
Patent proceedings outside the US
As previously disclosed, in Canada, in 2004, AstraZeneca brought
proceedings against Apotex Inc. (Apotex) for infringement of
several patents related to Losec. In February 2015, the Federal
Court of Canada (the Federal Court) found that Apotex had infringed
AstraZeneca's Losec formulation patent (Canadian Patent No.
1,292,693). Apotex appealed. In January 2017, the Federal Court of
Appeal upheld the trial court's findings of infringement and
validity. However, the Federal Court upheld one aspect of Apotex's
appeal relating to a limitation period defence, which may lower the
amount of damages owed by Apotex. A reference to determine patent
infringement damages is scheduled to commence in February 2017.
Product liability litigation
Farxiga (dapagliflozin)
As previously disclosed, in the US, AstraZeneca has been named
as a defendant in lawsuits involving plaintiffs claiming physical
injury, including diabetic ketoacidosis and kidney failure, from
treatment with Farxiga and/or Xigduo XR. Cases with these
allegations have been filed in several jurisdictions. As previously
disclosed, in October 2016 one of these cases was dismissed with
prejudice in favour of AstraZeneca. Since then, several other cases
have been dismissed either voluntarily or by the courts. Motions to
dismiss are pending in many of the jurisdictions where AstraZeneca
has been served.
As previously disclosed, in the US, counsel for plaintiffs in a
product liability action pertaining to Invokana (a product in the
same class as Farxiga) filed a motion with the Judicial Panel on
Multidistrict Litigation (JPML) seeking transfer of any currently
pending cases as well as any similar, subsequently filed cases to a
coordinated and consolidated pre-trial multidistrict litigation
(MDL) proceeding on a class-wide basis. In December 2016, the JPML
granted an MDL to only those plaintiffs alleging injury from
Invokana.
Onglyza/Kombiglyze (saxagliptin)
As previously disclosed, in the US, AstraZeneca is defending
various lawsuits filed in state and federal courts involving
multiple plaintiffs claiming heart failure, cardiac failure and/or
death from treatment with either Onglyza or Kombiglyze. In December
2016, plaintiffs in the California Superior Court filed a Petition
for Coordination with the Judicial Council of California,
requesting that all similar, currently pending or subsequently
filed cases in California be coordinated for pre-trial
purposes.
Nexium (esomeprazole)
As previously disclosed, in the US, AstraZeneca has been
defending product liability lawsuits brought in US federal and
state courts by approximately 1,900 plaintiffs who alleged that
Nexium caused osteoporotic injuries, such as bone deterioration,
loss of bone density and/or bone fractures, but all such claims
have now been dismissed with judgment entered in AstraZeneca's
favour. Approximately 270 plaintiffs appealed the dismissal of
their claims to the US Court of Appeals for the Ninth Circuit, and
fewer than 40 plaintiffs appealed the dismissal of their claims to
the California Second Appellate Division. In October 2016, the US
Court of Appeals for the Ninth Circuit affirmed the dismissal of
the approximately 270 claims in federal court. In January 2017, the
California Second Appellate Division affirmed the dismissal of the
less than 40 cases in California state court.
Commercial litigation
Crestor (rosuvastatin calcium)
As previously disclosed, in Israel, in November 2012, a Motion
to Certify a Claim as a Class Action and Statement of Claim
(together, a Motion to Certify) were filed in the District Court in
Tel Aviv, Jaffa, (the District Court) against AstraZeneca and four
other pharmaceutical companies for alleged deception and failure to
disclose material facts to consumers regarding potential adverse
events associated with certain drugs, including Crestor. In July
2013, an amended Motion to Certify containing similar allegations
to those in the first action were filed in the same District Court
against the same defendants. In November 2016, the plaintiff filed
a motion to withdraw from the action, which the District Court
granted in December 2016. This matter has now concluded.
Nexium Settlement anti-trust litigation
As previously disclosed, AstraZeneca is a defendant in a
multidistrict litigation class action and individual lawsuit
alleging that AstraZeneca's settlements of certain patent
litigation in the US relating to Nexium violated US anti-trust law
and various state laws. A trial in the US District Court for the
District of Massachusetts (the District Court) commenced in October
2014 and, in December 2014, a jury returned a verdict in favour of
AstraZeneca and entered judgment in favour of AstraZeneca in
September 2015. The plaintiffs appealed that judgment and, in
November 2016, the US Court of Appeals for the First Circuit
affirmed the District Court's decision. The plaintiffs petitioned
for rehearing and rehearing en banc, both of which were denied in
January 2017.
Telephone Consumer Protection Act litigation
In December 2016, in the US, AstraZeneca and several other
entities were served with a complaint filed in the US District
Court for the Southern District of Florida (the District Court)
that alleges, among other things, violations of the Telephone
Consumer Protection Act caused by the sending of unsolicited
advertisements by facsimile. AstraZeneca's motion to dismiss is
pending. The plaintiff also made a motion for class certification,
which, in January 2017, was denied without prejudice by the
District Court.
8 product analysis - FY 2016
Emerging
World US Europe Established ROW Markets
FY 2016 CER FY 2016 CER FY 2016 CER FY 2016 CER FY 2016 CER
$m % $m % $m % $m % $m %
Oncology:
Iressa 513 (5) 23 n/m 120 (5) 137 (8) 233 (10)
Tagrisso 423 n/m 254 n/m 76 n/m 83 100 10 100
Lynparza 218 n/m 127 81 81 n/m 3 n/m 7 n/m
Legacy:
Faslodex 830 19 438 23 228 11 68 15 96 25
Zoladex 816 - 35 25 156 (4) 270 (7) 355 6
Casodex 247 (9) 2 100 27 (7) 111 (23) 107 8
Arimidex 232 (6) 14 (26) 37 (24) 71 (18) 110 15
Others 104 (26) - n/m 8 (65) 71 7 25 (13)
Total Oncology 3,383 20 893 74 733 18 814 2 943 6
Cardiovascular &
Metabolic
Diseases:
Brilinta 839 39 348 45 258 15 44 22 189 80
Farxiga 835 72 457 75 187 52 58 72 133 96
Onglyza 720 (6) 376 (10) 132 (5) 70 11 142 (4)
Bydureon 578 - 463 (4) 100 23 11 25 4 (25)
Byetta 254 (19) 164 (22) 45 (25) 21 (9) 24 13
Legacy:
Crestor 3,401 (32) 1,223 (57) 866 (4) 591 (5) 721 12
Seloken/Toprol-XL 737 9 95 7 90 (5) 16 25 536 12
Atacand 315 (8) 36 6 97 (8) 20 (20) 162 (9)
Others 437 (26) 40 (27) 119 (17) 50 (21) 228 (30)
Total Cardiovascular &
Metabolic Diseases 8,116 (13) 3,202 (31) 1,894 1 881 (1) 2,139 8
Respiratory:
Symbicort 2,989 (10) 1,242 (18) 909 (12) 436 5 402 10
Pulmicort 1,061 8 174 (13) 99 (14) 90 (3) 698 21
Tudorza/Eklira 170 (9) 77 (25) 83 9 9 - 1 n/m
Daliresp/Daxas 154 48 134 29 15 100 1 n/m 4 n/m
Duaklir 63 n/m - - 60 n/m 2 n/m 1 n/m
Others 316 27 11 (39) 118 38 50 108 137 13
Total Respiratory 4,753 (3) 1,638 (16) 1,284 (4) 588 8 1,243 17
Other:
Nexium 2,032 (18) 554 (39) 251 (11) 537 (10) 690 (3)
Seroquel XR 735 (27) 515 (28) 134 (32) 17 (32) 69 (7)
Synagis 677 2 325 14 352 (7) - - - -
Losec/Prilosec 276 (17) 10 (44) 83 (13) 55 (31) 128 (9)
FluMist/Fluenz 104 (59) 33 (84) 64 3 6 (14) 1 n/m
Movantik/Moventig 91 n/m 90 n/m - - - - 1 -
Others 1,152 (20) 105 (54) 269 (21) 198 (27) 580 (4)
Total Other 5,067 (19) 1,632 (31) 1,153 (15) 813 (17) 1,469 (4)
Total Product Sales 21,319 (8) 7,365 (22) 5,064 (3) 3,096 (4) 5,794 6
9 product analysis - Q4 2016
Emerging
World US Europe Established ROW Markets
Q4 2016 CER Q4 2016 CER Q4 2016 CER Q4 2016 CER Q4 2016 CER
$m % $m % $m % $m % $m %
Oncology:
Iressa 118 (11) 7 75 29 (6) 36 (6) 46 (22)
Tagrisso 147 n/m 74 n/m 27 n/m 40 100 6 n/m
Lynparza 62 72 31 29 25 127 3 n/m 3 n/m
Legacy:
Faslodex 222 19 117 23 59 11 20 20 26 23
Zoladex 235 13 8 33 39 2 71 (9) 117 36
Casodex 60 (8) - - 8 14 27 (27) 25 13
Arimidex 57 (7) 2 (50) 10 (17) 18 (24) 27 22
Others 29 - - - 4 33 20 6 5 (29)
Total Oncology 930 26 239 61 201 26 235 11 255 16
Cardiovascular &
Metabolic
Diseases:
Brilinta 236 37 105 50 66 13 12 10 53 62
Farxiga 239 57 130 69 51 37 17 50 41 56
Onglyza 149 (21) 72 (27) 30 (6) 15 (17) 32 (23)
Bydureon 142 (8) 114 (7) 25 (7) 3 50 - n/m
Byetta 55 (22) 37 (14) 8 (43) 5 (29) 5 (25)
Legacy:
Crestor 631 (53) 95 (88) 209 (6) 146 (16) 181 14
Seloken/Toprol-XL 178 14 14 (26) 23 (4) 6 67 135 23
Atacand 81 (5) 8 14 23 (12) 5 25 45 (6)
Others 100 (31) 13 (7) 30 (21) 12 (29) 45 (41)
Total Cardiovascular &
Metabolic Diseases 1,811 (26) 588 (52) 465 (3) 221 (11) 537 6
Respiratory:
Symbicort 740 (13) 284 (31) 230 (3) 126 15 100 5
Pulmicort 288 8 36 (31) 26 (10) 29 - 197 25
Tudorza/Eklira 36 (23) 16 (36) 18 (5) 2 - - n/m
Daliresp/Daxas 41 28 33 3 5 100 - - 3 n/m
Duaklir 19 58 - - 18 46 1 n/m - -
Others 86 37 4 (33) 35 85 17 143 30 (3)
Total Respiratory 1,210 (5) 373 (29) 332 5 175 19 330 16
Other:
Nexium 491 (15) 135 (23) 61 (19) 148 (5) 147 (12)
Seroquel XR 118 (51) 71 (60) 28 (32) 3 (40) 16 (16)
Synagis 302 10 154 20 148 1 - - - -
Losec/Prilosec 59 (23) 3 100 20 (19) 13 (33) 23 (30)
FluMist/Fluenz 67 (60) 20 (83) 43 (21) 4 (43) - -
Movantik/Moventig 26 73 26 73 - - - - - -
Others 246 (34) 9 (84) 34 (57) 25 (69) 178 8
Total Other 1,309 (25) 418 (38) 334 (21) 193 (28) 364 (5)
Total Product Sales 5,260 (15) 1,618 (37) 1,332 (3) 824 (6) 1,486 7
Shareholder Information
Announcement of first quarter 2017 results 27 April 2017
Annual General Meeting 27 April 2017
Announcement of half year and second quarter 2017 results 27 July 2017
Announcement of nine months and third quarter 2017 results 9 November 2017
Future dividends will normally be paid as follows:
First interim Announced with half-year and second-quarter results and paid in September
Second interim Announced with full-year and fourth-quarter results and paid in March
The record date for the second interim dividend for 2016,
payable on 20 March 2017, will be 17 February 2017. Ordinary Shares
listed in London and Stockholm will trade ex-dividend from 16
February 2017. American Depositary Shares listed in New York will
trade ex-dividend from 15 February 2017.
The record date for the first interim dividend for 2017, payable
on 11 September 2017, will be 11 August 2017. Ordinary Shares
listed in London and Stockholm will trade ex-dividend from 10
August 2017. American Depositary Shares listed in New York will
trade ex-dividend from 9 August 2017.
Trademarks of the AstraZeneca group of companies and of
companies other than AstraZeneca appear throughout this document in
italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca
symbol are all trademarks of the AstraZeneca group of companies.
Trademarks of companies other than AstraZeneca that appear in this
document include Duaklir Genuair, Duaklir, Eklira, and Tudorza,
trademarks of Almirall, S.A.; Toprol-XL, a trademark of Aralez
Pharmaceuticals Inc.; Epanova, a trademark of Chrysalis Pharma AG;
Rhinocort Aqua, a trademark of Cilag GmbH International (outside
the US); Zinforo, a trademark of Forest Laboratories; Invokana, a
trademark of Johnson & Johnson/Janssen Pharmaceutica NV; and
Zavicefta, a trademark of Pfizer Inc.
Addresses for Correspondence
Registered Office Registrar and Swedish Central Securities US Depositary
1 Francis Crick Avenue Transfer Office Depository Citibank Shareholder Services
Cambridge Biomedical Campus, Equiniti Limited Euroclear Sweden AB PO Box 43077
Cambridge Aspect House PO Box 191 Providence
CB2 0AA Spencer Road SE-101 23 Stockholm RI 02940-3077
UK Lancing Sweden USA
West Sussex
BN99 6DA
UK
Tel: +44 (0)20 3749 5000 Tel (freephone in UK): Tel: +46 (0)8 402 9000 Tel: (toll free in the US)
0800 389 1580 +1 (888) 697 8018
Tel (outside UK): Tel: (outside the US)
+44 (0)121 415 7033 +1 (781) 575 4555
citibank@shareholders-online.c
om
Cautionary Statements Regarding Forward-Looking Statements
In order, among other things, to utilise the 'safe harbour'
provisions of the US Private Securities Litigation Reform Act 1995,
we are providing the following cautionary statement: This document
contains certain forward-looking statements with respect to the
operations, performance and financial condition of the Group,
including, among other things, statements about expected revenues,
margins, earnings per share or other financial or other measures.
Although we believe our expectations are based on reasonable
assumptions, any forward-looking statements, by their very nature,
involve risks and uncertainties and may be influenced by factors
that could cause actual outcomes and results to be materially
different from those predicted. The forward-looking statements
reflect knowledge and information available at the date of
preparation of this document and AstraZeneca undertakes no
obligation to update these forward-looking statements. We identify
the forward-looking statements by using the words 'anticipates',
'believes', 'expects', 'intends' and similar expressions in such
statements. Important factors that could cause actual results to
differ materially from those contained in forward-looking
statements, certain of which are beyond our control, include, among
other things: the loss or expiration of, or limitations to,
patents, marketing exclusivity or trademarks, or the risk of
failure to obtain and enforce patent protection; the risk of
substantial adverse litigation/government investigation claims and
insufficient insurance coverage; effects of patent litigation in
respect of IP rights; exchange rate fluctuations; the risk that
R&D will not yield new products that achieve commercial
success; the risk that strategic alliances and acquisitions,
including licensing and collaborations, will be unsuccessful; the
impact of competition, price controls and price reductions;
taxation risks; the risk of substantial product liability claims;
the impact of any delays in the manufacturing, distribution and
sale of any of our products; the impact of any failure by third
parties to supply materials or services; the risk of failure of
outsourcing; the risks associated with manufacturing biologics; the
risk of delay to new product launches; the difficulties of
obtaining and maintaining regulatory approvals for products; the
risk of failure to adhere to applicable laws, rules and
regulations; the risk of failure to adhere to applicable laws,
rules and regulations relating to anti-competitive behaviour; the
risk that new products do not perform as we expect; failure to
achieve strategic priorities or to meet targets or expectations;
the risk of an adverse impact of a sustained economic downturn;
political and socio-economic conditions; the risk of environmental
liabilities; the risk of occupational health and safety
liabilities; the risk associated with pensions liabilities; the
risk of misuse of social medial platforms and new technology; the
risks associated with developing our business in emerging markets;
the risk of illegal trade in our products; the risks from pressures
resulting from generic competition; the risk of failure to
successfully implement planned cost reduction measures through
productivity initiatives and restructuring programmes; economic,
regulatory and political pressures to limit or reduce the cost of
our products; the risk that regulatory approval processes for
biosimilars could have an adverse effect on future commercial
prospects; the impact of failing to attract and retain key
personnel and to successfully engage with our employees; the impact
of increasing implementation and enforcement of more stringent
anti-bribery and anti-corruption legislation; and the risk of
failure of information technology and cybercrime. Nothing in this
document/presentation/webcast should be construed as a profit
forecast.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR LLFLAFVILIID
(END) Dow Jones Newswires
February 02, 2017 02:00 ET (07:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
